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ABSTRACT OF DISSERTATION 
 
 
 
 
EFFECTS OF GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR 
   (GDNF) ON STEM/PROGENITOR CELL  
PROLIFERATION AND DIFFERENTIATION 
 
 
Stem/progenitor cells are present in the adult brain; they undergo constant 
proliferation and differentiate into mature neurons in certain brain areas, a phenomenon 
called neurogenesis. This study investigated the effects of GDNF, a potent trophic factor 
of dopaminergic neurons, on neurogenesis in the brain. Nestin and 5-Bromo-2’-
deoxyuridine (BrdU) were used as stem/progenitor cells markers. 
First, we observed extensive bilateral increases of stem/progenitor cells in the 
dentate gyrus and substantia nigra after continuous infusion of GDNF into the normal rat 
brain. However, none of the BrdU+ cells showed neuronal features in the substantia nigra 
as characterized by immunocytochemical procedures. Next, we identified the 
morphology of BrdU+ cells after infusing the marker into the brain. While the procedures 
increased the BrdU labeling, neurogenesis was not observed in the basal ganglia. Under 
electron microscope, the BrdU+ cells either were undifferentiated or showed 
characteristics of astrocytes. This observation is consistent with suggestions that 
astrocytes serve as multipotent progenitors. Later, we repeated GDNF intrastriatal 
infusion one month after a severe 6-hydroxydopamine (6-OHDA) lesion. The number of 
BrdU+ cells was significantly higher in the GDNF recipients in the ipsilateral substantia 
nigra and both sides of the dentate gyrus. However, no neurogenesis was observed. In 
addition, motor functions were not improved by GDNF treatment. Thus, we measured the 
effects of GDNF administration directly into the substantia nigra six hours before a 
partial 6-OHDA lesion. HPLC measurements of dopamine and its metabolites showed a 
significant increase of tissue level in the substantia nigra and striatum, respectively. 
Despite this, no newly generated dopaminergic neurons was detected in the basal ganglia. 
Taken together, our studies investigated the effects of GDNF on adult 
stem/progenitor cells in normal and lesioned rat brain. For the first time, we demonstrated 
that GDNF promoted their proliferation in the dentate gyrus, suggesting it has a role in 
neurogenesis and the function of learning and memory. In each scenario, GDNF 
promoted stem/progenitor cell proliferation, but failed to induce neurogenesis in the 
substantia nigra. We believed that the local microenvironment in the substantia nigra may 
prevent the stem/progenitor cells to mature into functional neurons. 
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Chapter One 
 
 
Effects of Glial Cell Line-Derived Neurotrophic Factor (GDNF)  
on Stem/progenitor Cell Proliferation and Differentiation 
 
 
 
Glossary 
3-MT   3-methoxytyramine 
6-OHDA  6-hydroxydopamine 
ABC   avidin: biotin: peroxidase complex 
aCSF   artificial cerebrospinal fluid 
ANOVA   analysis of variance 
ARTN   artemin 
ICC   immunocytochemistry 
BDNF   brain-derived neurotrophic factor 
bFGF   basic fibroblast growth factor 
BrdU   5-bromo-2’-deoxyuridine 
CNS   central nervous system 
CNTF   ciliary neurotrophic factor 
COMT   catechol-O-methyltransferase 
DAB   diaminobenzidine 
DAT   dopamine transporter 
 2 
DMSO   dimethyl sulfoxide 
DOPAC  3,4-dihydroxyphenylacetic acid 
EGF   epidermal growth factor 
EGFR   EGF receptor 
GABA   γ-aminobutyrate acid 
GAD   glutamate acid decarboxylase 
GDNF   glial cell line-derived neurotrophic factor 
GFAP   glial fibrillary acidic protein 
GFP   green fluorescent protein 
GFRα   GDNF family receptor α 
GPI   glycosylphosphatidylinositol 
HPLC   high performance liquid chromatography 
HVA   homovanillic acid  
ICC   immunocytochemistry 
i.c.v.   intracerebroventrical 
IGF-1   insulin growth factor-1 
i.p.   intraperitoneal 
LV   lateral ventricle 
MAO   monoamine oxidase  
MAP-2  microtubule-associated protein-2 
MFB   medial forebrain bundle  
MPTP   1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
NCAM  neural cell adhesion molecule 
 3 
NeuN   neuronal nuclei  
NGF   nerve growth factor 
NSE   neuron specific enolase  
NTN   neurturin 
PD   Parkinson’s disease  
PSP   persephin 
RT-PCR  reverse transcription polymerase chain reaction 
SGZ   subgranular zone 
SNpc   substantia nigra pars compacta 
SVZ   subventricular zone 
TGF α   transforming growth factor α 
TGF β   transforming growth factor β 
TH   tyrosine hydroxylase  
TMB   3,3’,5,5’-tetramethylbenzidine 
VTA   ventral tegmental area 
  
Background 
 
Stem cells in the central nervous system (CNS) 
Stem cells are undifferentiated and unspecialized cells that can divide to 
reproduce themselves and/or give rise to one or more specialized types of cells. To be 
considered a stem cell in the CNS, a cell must have multipotency: the potential to 
differentiate into all three cell lineages including neurons, astrocytes, and 
 4 
oligodendrocytes. Besides, it should have a capacity for unlimited self-renewal 
throughout the adulthood and will never differentiate (Weiss et al. 1997). A progenitor 
cell is, by definition, a cell producing terminally differentiated cells through a limited 
capacity for self-renewal (McKay, 1997). The term “precursor” is less stringent, referring 
to any cell that is earlier in a developmental pathway than another. It is often used when it 
is not clear whether a stem cell or a progenitor cell has been studied. “Plasticity” is 
referred to as the ability of the adult brain to change its anatomy in response to external 
or internal stimuli. 
Stem cells have two potential mitotic pathways, the symmetric division and the 
asymmetric division. When a stem cell undergoes symmetric division, both of the 
progeny will be stem cells. With asymmetric division, a stem cell produces two daughter 
cells. One is a stem cell whereas the other is a progenitor cell that begins a pathway 
towards terminal differentiation. Thus, a stem cell has the ability to generate a large 
number of differentiated cells through an extensive self-renewal and production of 
progenitor cells.  
It was once thought that the capability for stem cells to proliferate and produce 
different cell types was restricted to the embryonic stage; and recovery from brain injury 
occurred only by building up new synaptic connections between remaining healthy cells. 
The scarce proliferation activity within the CNS was attributed solely to the generation of 
glia, the process called gliogenesis. New evidence shows the existence of multipotent 
stem cells along the subventricular zone (SVZ, Bayer et al. 1982; Crespo et al. 1986; 
Reynolds and Weiss, 1992; Richards et al. 1992) and in the subgranular zone (SGZ, Gage 
et al. 1995; Palmer et al. 1997) of the hippocampus in the adult brain. SVZ is a 2–3 cell 
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layer-thick region immediately adjacent to the ependymal lining of the lateral ventricle 
derived from the embryonic germinal zone of the forebrain; it borders the striatum, 
septum and corpus callosum. SGZ is a thin lamina between the hilar region and the 
granular cell layer of the dentate gyrus. 
The introduction of [3H] thymidine labeling techniques allowed the discovery of 
persistent proliferation existing throughout the adulthood in the SVZ and the SGZ 
(Altman, 1962; Altman & Das, 1965a,b). The use of a thymidine analogue, 5-Bromo-2’-
deoxyuridine (BrdU), further confirmed the existence of stem/progenitor cells in these 
two brain areas. 
The cells isolated from many brain areas, including the SVZ, the SGZ, the cortex, 
the striatum, and the substantia nigra have been shown to be able to expand indefinitely 
in vitro with growth factor such as basic fibroblast growth factor (bFGF) and epidermal 
growth factor (EGF). With growth factor withdrawn, they could further differentiate into 
neurons, astrocytes and oligodendrocytes (Reynolds & Weiss, 1992; Richards et al. 
1992). When transplanted back into the SVZ or SGZ, where neurogenesis constantly took 
place, they could further give rise to newly generated functional neurons (Lie et al. 2002). 
 
Adult cell genesis-neurogenesis and gliogenesis 
Neurogenesis, the production of new neurons, has only been identified 
unequivocally in two regions of the CNS: the dentate gyrus of the hippocampus and the 
olfactory bulb. It is only within the last decade that the existence of neurogenesis in adult 
brain has been widely accepted. The concept was first introduced by Altman & Das 
(1962; 1965a,b) in adult rats with [3H] thymidine autoradiography. But this method has 
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two shortcomings. One is that it is hard to prove the identity of the mitotic cells as 
neurons; the other is the difficulty to measure the extent of neurogenesis quantitatively.  
With the introduction of techniques like BrdU labeling and green fluorescent 
protein (GFP) transfection, it is now clear that neurogenesis does exist in certain brain 
areas. The stem/progenitor cells residing in the SVZ can migrate to the olfactory bulb 
through the rostral migratory stream and differentiate into interneurons (Lustin, 1993; 
Lois & Alvarez-Buylla, 1994), and those in the SGZ can migrate to the nearby dentate 
gyrus and differentiate into the granule cells (Cameron et al. 1993; Kuhn et al. 1996; 
Palmer et al. 2000; Seri et al. 2001). 
Several criteria have been used to identify a functional newly generated neuron. 
These include being postmitotic, polarized, capable of firing action potentials and able to 
communicate with other neurons through synapses. Up to date, studies on neurogenesis 
have relied mostly on morphological or immunohistochemical evidence. There is still a 
long way to go in investigating the identity and location of newly generated cells. 
 
Neurotrophic factors 
Neurotrophic factors, by definition, are endogenous soluble proteins that promote 
the long term survival, differentiation and maintenance of neurons (Barde, 1989; Gotz 
and Schartl, 1994). It is now generally accepted that they are signaling molecules 
important for the development and maintenance of structural integrity within the 
peripheral and central nervous systems. They are generally small, soluble proteins with 
molecular weights between 13 and 24 KDa and are often active as homodimers.  
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Like most signaling molecules, neurotrophic factors can be divided into families 
formed of closely related molecules. They are produced by both glial cells and neurons. 
A prototypic neurotrophic factor, such as nerve growth factor (NGF), is a target-derived 
molecule that binds to a transmembrane receptor on the cell surface (Barbacid 1995; 
Segal and Greenberg, 1996). The receptor then dimerizes and is activated by 
transphosphorylation of the catalytic intracellular domain, which starts a complex 
intracellular signaling pathway leading to immediate, early and late transcriptional 
changes in the target cell. Some of the neurotrophic factors, such as the ciliary 
neurotrophic factor (CNTF), are also secreted, but not derived from a distant target tissue. 
These molecules are produced in an autocrine or paracrine fashion and exert their 
function on neuronal cells. Some other neurotrophic factors, including integrins, are not 
secreted and have initially been considered as adhesion molecules. They are now found to 
have growth-promoting functions, such as mediating cell differentiation. 
It is well known that excess neurons are generated during neural development. 
The survival and differentiation of an appropriate number of neurons is largely regulated 
by target-derived neurotrophic factors. Developing neurons that fail to compete and make 
connections with their targets will be deprived of necessary neurotrophic factors and die. 
Those neurons that establish connections survive and function properly. 
Neurotrophic factors are also capable of promoting the re-growth of damaged 
neurons and their processes both in vitro and in animal models. Thus, they represent 
exciting possibilities for reversing devastating brain disorders, including Parkinson's 
disease (PD). 
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Neurotrophic factors and cell genesis 
Neurotrophic factors are also known to increase adult neurogenesis (Goldman, 
1998). They are endogenous soluble small proteins that promote the survival and 
maintenance of neurons. Below are several examples of their involvement in 
neurogenesis. 
(1) Intracerebroventrical (i.c.v.) injections of EGF increased the proliferation of 
stem/progenitor cells in the SVZ and lead to differentiation of the stem cells into glia and 
the reduction of newborn neurons in the hippocampus and the olfactory bulb (Craig et al. 
1996; Kuhn et al. 1997). EGF also maintained and stimulated proliferation of adult stem 
cells in vitro (Reymolds & Weiss, 1992). 
(2) FGF stimulated the proliferation of neural stem cells and promoted neuronal 
production in many brain regions including the olfactory bulb (Kuhn et al. 1997). It could 
stimulate adult stem cell proliferation and maintain them in vitro (Richards et al. 1992). 
(3) Brain-derived neurotrophic factor (BDNF) administration has been shown to 
induce neurogenesis in the striatum, septum, thalamus, hypothalamus, and olfactory bulb 
(Zigova et al. 1998; Benraiss et al. 2001; Pencea et al. 2001). 
(4) Insulin growth factor -1 (IGF-1) promoted the proliferation of stem cells and 
support cell survival (Anderson et al. 2002). 
(5) Transforming growth factor α (TGFα) administration, may promote stem cell 
proliferation, migration and differentiation into dopaminergic neurons in the striatum 
(Fallon et al. 2000), but the results are controversial (Cooper & Isacson, 2004; 
Frielingsdorf et al. 2004). 
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GDNF and its receptors 
GDNF (Lin et al., 1993) and the related proteins neurturin (NTN) (Kotzbauer et 
al., 1996), persephin (PSP) (Milbrandt et al., 1998) and artemin (ARTN) (Baloh et al., 
1998) define a novel family of neurotrophic factors that is a sub-group of the 
transforming growth factor β (TGFβ) superfamily.  
Unlike other members of the TGFβ superfamily, which signal through the 
receptor serine-threonine kinases, GDNF family ligands activate intracellular signaling 
cascades via receptor tyrosine kinase. The receptors of the GDNF family ligands have 
multiple components. They include a signaling unit, the membrane-spanning receptor 
tyrosine kinase RET (Durbec et al. 1996; Trupp et al. 1996), and a high-affinity ligand 
binding protein, the GDNF family receptor α (GFRα, Jing et al. 1996; Treanor et al. 
1996). As depicted in Fig. 1.1., GDNF family ligands first bind to the 
glycosylphosphatidylinositol (GPI)-anchored GFRα, and then the GDNF family ligand–
GFRα complex binds to and stimulates autophosphorylation of RET (Trupp et al. 1998; 
Rosenthal, 1999). Alternatively, a pre-associated complex between GFRα and RET could 
form the binding site for the GDNF family ligand (Eketjall et al. 1999). GFRα1, GFRα2, 
GFRα3 and GFRα4 are the physiological co-receptors for GDNF, NTN, ARTN and PSP, 
respectively (Airaksinen & Saarma, 2002). 
The first member of this family, GDNF, is a glycosylated and disulfide-bound 
homodimer. The biologically active form of GDNF is composed of two 134 amino acid 
monomers that migrate in gels with an apparent molecular weight in the 33-45 kDa 
range. Although all GDNF family ligands could signal via activated RET, GDNF can 
also signal via GFRα1 in the absence of RET (Trupp et al. 1998). GPI-anchored GFRα 
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receptors are localized in plasma membrane to lipid rafts. GDNF binding to GFRα1 also 
recruits RET to the lipid rafts and triggers association with Src, which is required for 
effective downstream signaling, leading to differentiation and neuronal survival.  
Alternatively, a multicomponent receptor system consisting of GFRα-1 and 
neural cell adhesion molecule (NCAM, Paratcha et al., 2003) could be activated by 
GDNF. NCAM is abundantly expressed in Schwann cells and the hippocampal and 
cortical neurons (Crossin & Krushel, 2000). NCAM-deficient mice displayed structural 
abnormalities in the rostral migratory bulb, the olfactory bulb, and the hippocampus, as 
well as the functional deficits in learning and memory (Tomasiewicz et al. 1993; Cremer 
et al. 1994; Cremer et al. 1997; Chazal et al. 2000). This suggests that GDNF may utilize 
NCAM signaling pathways to promote axonal growth in hippocampal and cortical 
neurons in a RET-independent way. A recent publication by Enomoto et al (2004) 
challenged this idea with the use of specific transgenic mice that express GFRα1 under a 
RET promoter on a GFRα1 null background. Although these mice lack all RET-
independent GFRα1 expression, no structural abnormalities in the olfactory bulb and the 
hippocampus were detected. 
The mRNA expression of GDNF and its receptor has been identified in many 
tissues and species by a variety of techniques, including in situ hybridization (Hellmich et 
al., 1996; Suvanto et al., 1996), RNase protection (Trupp et al., 1995), and reverse 
transcription polymerase chain reaction (RT-PCR) (Choi-Lundberg and Bohn, 1995). 
GDNF was found to be first expressed in the rostral part of the mouse neural plate at the 
embryonic day 7.5 and then in the anterior neuroectoderm until embryonic day 10.5 
(Hellmich et al., 1996; Suvanto et al., 1996). From the late embryonic stage until 
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adulthood, the GDNF mRNA expression could be seen in the target areas for nigral 
dopamine neurons including the caudate, putamen, globus pallidus, and nucleus 
accumbens (Choi-Lundberg and Bohn, 1995; Trupp et al., 1997). GDNF mRNA could 
also be detected in ventromedial and ventrolateral thalamic nuclei at high levels and 
throughout the hippocampus at low levels. Several neuronal populations responsive to 
GDNF express RET. These include dopaminergic neurons in the substantia nigra and 
spinal motoneurons. On the other hand, mRNA of GFRα-1 is expressed in many more 
areas of the brain. A high level of GFRα-1 mRNA is expressed in both dopaminergic and 
GABAergic neurons in the substantia nigra (Sarabi et al. 2001). GFRα-1 mRNA 
expression is also found in the GABAergic neurons in the cortex, hippocampus, reticular 
thalamic nucleus and septum as well as by cells in the cerebellum and motoneurons in the 
spinal cord (Sarabi et al., 2000, 2003).  This suggests that GDNF can effect many 
different cell populations in the brain, including nigral dopaminergic and GABAergic 
neurons. 
 
Function of GDNF in the brain 
GDNF family ligands are potent survival factors for midbrain dopaminergic 
neurons, as well as for other forms of neurons. Early studies on GDNF provided strong 
evidence that it is essential for the survival, differentiation and high-affinity dopamine 
uptake of midbrain dopaminergic neurons in vivo and in vitro (Lin et al., 1993). GDNF 
specifically affects cultured dopaminergic midbrain neurons without affecting other 
neurons or glia of the substantia nigra (Lin, 1996). It increases dopaminergic cell number, 
dopamine uptake, cell size and axon sprouting (Hudson et al., 1995; Ai et al. 2003) 
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without any change in γ-aminobutyrate acid (GABA) or serotonin uptake or overall 
number of neurons.  
With the use of GDNF knock-out mice and transgenic mice, Granholm et al 
(2000) found that postnatal development of dopaminergic neurons was severely disturbed 
as a result of the GDNF null mutation. This suggests that GDNF is essential for postnatal 
survival and/or TH expression of ventral mesencephalic dopaminergic neurons. 
GDNF was also found to have trophic effects on many other populations of 
neurons in vivo and in vitro, including spinal motoneurons (Henderson et al., 1994; 
Oppenheim et al., 1995; Yan et al., 1995), central noradrenergic neurons (Arenas et al., 
1995), cerebellar Purkinje cells (Mount et al. 1995), and peripheral neurons (Buj-Bello et 
al., 1995; Trupp et al., 1995). GDNF is also required for promoting ureteric branching in 
kidney development and regulating spermatogenesis.  
GDNF has also been shown to act as a target-derived factor in the olfactory 
system and may prolong the lifespan of the receptor neurons, hence allowing them time 
for differentiation (Buckland & Cunningham, 1999).  
 
Effects of GDNF on learning and memory 
GDNF is a potent trophic factor for midbrain dopaminergic neurons innervating 
the hippocampus (Ishikawa et al. 1982). Thus, GDNF may promote neuronal survival and 
enhance plasticity in hippocampal neurons (Lindvall et al. 1994). Upon insult to the 
brain, there was evidence of activity-dependent alterations in GDNF mRNA expression 
within the hippocampus (Reeben et al. 1998; Kokaia et al. 1999). An i.c.v. administration 
of GDNF improved spatial learning in aged rats (Pelleymounter et al. 1999).  
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It has also been reported (Gerlai et al. 2001) that heterozygous GDNF mutant 
mice demonstrated significant and selective impairment of performance in the Morris 
water maze without detectable blood chemical and pathological changes. The Morris 
water maze test is a widely used spatial task of learning and memory that mainly involves 
the hippocampus. This suggested that endogenous GDNF may play a critical role in 
cognitive function. 
The noradrenergic locus coeruleus-hippocampal pathway is important in the 
process of learning and memory. GDNF is a potent neurotrophic factor on locus 
coeruleus noradrenergic neurons. By using wild type or GDNF knockout fetus brain 
transplantation, Quintero et al. (2004) have unequivocally shown that the normal 
development of this pathway was disrupted by GDNF null mutation. This also suggests 
that GDNF may play an essential role in learning and memory. 
Up to now, there has been no published report on the mechanism through which 
GDNF could exert its function on the brain regions related to learning and memory, 
especially in the hippocampus. 
 
Effects of GDNF on neurogenesis 
As a potent trophic factor for dopaminergic neurons, GDNF exerts its function 
through targeting the nigrostriatal system, especially the striatum and the substantia nigra. 
Both of these structures have endogenous stem/progenitor cells. Stem/progenitor cells 
were observed and isolated from the adult striatum with maintained proliferative activity 
(Palmer et al. 1995; Kuhn et al. 1997; Mao et al. 2001). The addition of new neurons has 
been shown in the adult striatum in normal squirrel monkeys (Bedard et al. 2002) and in 
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rodents under neurotrophic factor treatments (Craig et al. 1996; Fallon et al. 2000; 
Benraiss et al. 2001; Pencea et al. 2001). These new neurons might be derived from the 
endogenous striatal progenitor cells or from the neighboring stem/progenitor cells in the 
SVZ. There is recent evidence that dopaminergic neurites exist in close contact with 
stem/progenitor cells in the SVZ (Hoglinger et al. 2004), suggesting a possible role of 
GDNF on these cells. Endogenous stem/progenitor cells were also observed and isolated 
from the substantia nigra. They had the ability to differentiate into glial cells in vivo and 
to produce all cell lineages in vitro (Lie et al. 2002). When transplanted back into the 
hippocampus, these stem/progenitor cells could survive and differentiate into neurons, 
suggesting an important role of the local environment in promoting neurogenesis. These 
cells may also be responsive to GDNF treatment, which could serve as a proneuronal 
signal. 
Although GDNF levels decrease markedly after development, the endogenous 
level of GDNF could increase after certain experiences, such as an enriched environment 
(Young et al. 1999). Dopaminergic fibers have been identified in the SGZ of the 
hippocampus, and dopaminergic denervation caused the loss of these fibers in mice 
(Hoglinger et al. 2004). These reports suggest that hippocampal neurogenesis may be 
partly under dopaminergic control. Since exposure to an enriched environment has been 
shown to promote survival of newly generated neurons in the dentate gyrus 
(Kempermann et al. 1997), it is possible that GDNF could play a role in hippocampal 
neurogenesis. Could GDNF serve as a proneuronal signal and induce neurogenesis in the 
striatum, the hippocampus, and the substantia nigra? We aim to answer these questions in 
the following experiments.  
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Experimental Design 
In this research project, we designed a series of experiments to answer some of 
the following questions: a) Will GDNF continuous intrastriatal infusion be sufficient to 
induce neurogenesis in normal animals? b) What is the morphology of the newly 
generated cells in the brain? c) Will GDNF continuous intrastriatal infusion improve 
motor function of animals with severe 6-OHDA lesion and induce neurogenesis in the 
brain besides its restorative effects? d) Will GDNF intranigral injection induce 
neurogenesis in the substantia nigra in addition to protecting dopaminergic neurons from 
6-OHDA partial lesion? 
 
Study 1: Effects of GDNF continuous infusion into the striatum of normal rats (n=9) 
Pump                                          
Implantation                               Perfusion 
          GDNF/aCSF Infusion 
Day 1    Day 29 
                      Day 5 
       BrdU Injections 
 
 
Study 2: Characteristics of BrdU labeled cells with BrdU continuous infusion into 
the lateral ventricle of normal rats  
(n=6 for electron microscopy; n=4 for immunofluorescent study) 
       Pump                                          
   Implantation                                 Perfusion 
                  BrdU Infusion  
     Day 1                              Day 29 
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Study 3: Effects of GDNF continuous infusion into the striatum of  
6-hydroxydopamine (6-OHDA)-lesioned rats (n=9) 
6-OHDA   Pump                                          
MFB Lesion   Implantation                               Perfusion 
          GDNF/aCSF Infusion 
Day 1    Day 30   Day 58 
                                                      Day 35 
                                                             BrdU Injections 
             
                                 Behavior test days indicated by arrows 
 
Study 4: Effects of GDNF on rat brain when delivered in the substantia nigra six 
hours before a 6-OHDA lesion (n=8) 
 
GDNF/Citrate      6-OHDA 
Injection      Lesion                                        
                6 hr                               Perfusion 
 
     Day 1                              Day 29 
                   Day 5      
              BrdU Injections 
 
 
Concluding Remarks 
The focus of this dissertation research has been to investigate the effect of GDNF 
on stem/progenitor cell proliferation and differentiation during the adulthood. Because 
GDNF is a potent trophic factor for dopaminergic neurons and it may play a role in 
learning and memory, we focus our research on the basal ganglia and the hippocampus. 
The main hypotheses were tested in four specific aims: 
1. Continuous striatal infusion of GDNF/TGFα will induce 
stem/progenitor cells to proliferate and differentiate into cells 
expressing neuronal marker proteins, confirming and extending the 
findings of Fallon et al (2000). 
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2. Delivery of BrdU through continuous i.c.v. infusion will label more 
stem/progenitor cells than through repeated i.p. injection; this technique 
will allow the detection of newly generated neurons in the basal 
ganglia. This work is to confirm and extend the work by Zhao et al 
(2003). 
3. Continuous infusion of GDNF into the striatum of rats with unilateral 6-
OHDA medial forebrain bundle (MFB) lesions will improve motor 
function and induce stem/progenitor cells to proliferate and differentiate 
into cells expressing neuronal marker proteins.  
4. A single intranigral injection of GDNF into the rat brain six hours 
before a unilateral 6-OHDA lesion will protect dopaminergic neurons 
against the neurotoxin, increase the tissue level of dopamine and its 
metabolites, and induce stem/progenitor cells to proliferate and 
differentiate into cells expressing neuronal marker proteins. This is to 
confirm and extend the results from Kearns et al (1997). 
The data will be presented from Chapter 2 to Chapter 5 in this thesis. In Chapter 
2, we first demonstrated that continuous infusion of GDNF could induce stem/progenitor 
cell proliferation and migration in the basal ganglia and the dentate gyrus, but not 
neurogenesis in the substantia nigra. The techniques we used were ICC and 
immunofluoresence. In Chapter 3, we used immunofluorescent confocal microscopy and 
electron microscopy techniques to investigate the identity of the BrdU positive cells with 
BrdU continuous infusion, and concluded that the cells labeled with BrdU were immature 
and had characteristics of an astrocyte. Apomorphine-induced rotation tests were used 
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and the results showed no significant functional recovery with GDNF treatment in this 
scenario. In Chapter 4, a unilateral 6-OHDA MFB lesion was first introduced to animals 
one month before the GDNF treatment, thus wiping out more than 95% of the 
dopaminergic neurons in the ipsilateral substantia nigra. We found that GDNF continuous 
infusion could induce stem/progenitor cell proliferation, but not neurogenesis, in the 
substantia nigra. In addition to ICC, we used an apomorphine-induced rotation test to 
monitor the recovery of motor function in trophic factor recipients. In Chapter 5, a single 
GDNF intranigral injection was administered to rat brain prior to a less severe lesion in 
the substantia nigra, but still failed to induce neurogenesis in the substantia nigra. High 
performance liquid chromatography (HPLC) was used to confirm the increased tissue 
level of dopamine and its metabolites in the substantia nigra with GDNF treatment. 
In summary, our findings provided evidence that GDNF induced stem/progenitor 
cell proliferation in the basal ganglia and hippocampus. No neurogenesis could be 
observed in the substantia nigra under the GDNF treatment, even with lesion. On the 
other hand, GDNF may play a role in promoting neurogenesis in the dentate gyrus, where 
neurogenesis constantly occurs, with or without injury. 
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Figure 1.1 – Procedures of GDNF binding to RET. A GDNF dimer first binds to two 
GFRα1 molecules to form a ligand-receptor complex (A). This complex then binds to 
two RET molecules, which dimerizes and undergoes antophosphorylation of the 
tyrosine kinase domain in each subunit (B). Upon this, the RET dimer is activated and 
starts the downstream signaling pathway. 
 
Figure modified from p18 of the thesis entitled “GDNF and p75 neurotrophin receptor 
in development and disease” by Wartiovaara K, 1998. 
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Chapter Two 
 
Continuous Intrastriatal Infusion of GDNF Increases Cell Genesis  
in the Striatum, Hippocampus and Substantia Nigra 
 
Summary 
The purpose of this study was to analyze the effects of intrastriatal GDNF and 
TGFα administration on neurogenesis in the striatum, hippocampus and substantia nigra. 
The results were analyzed to assess the capability of continuous GDNF/TGFα infusion to 
activate endogenous adult stem cells and to stimulate their proliferation and 
differentiation into mature glia and neurons. Using Alzet minipumps (model 2004, 
Durect, Cupertino, CA), the control group of nine rats received vehicle (artificial 
cerebrospinal fluid, aCSF) infusion into the right striatum at a rate of 0.5 µl/hr for 28 
days (Fig. 2.1.).  The two trophic factor recipient groups received either recombinant-
Methionyl human GDNF (1.5 µg/µl, Amgen, Thousand Oaks, CA) or TGFα (0.5µg/µl, 
PeproTech Inc., Rocky Hill, NJ) at the same flow rate for the same time period with nine 
animals (n=9) in each group. To label mitotic cells, all animals received intraperitoneal 
(i.p.) injections of 200 mg/kg 5-Bromo-2’-deoxyuridine (BrdU, Sigma, St. Louis, MO) 
for the first five days of intrastriatal infusion.  After 28 days of infusion with the trophic 
factor recipients receiving a total of 600 µg GDNF or 200 µg TGFα, the animals were 
euthanized and their brains recovered for immunocytochemical (ICC) analysis at the light 
microscopic level (Table 2.1.; Fig. 2.2.).  The spread of GDNF in brain parenchyma was 
evaluated by GDNF ICC (Fig. 2.3.).  Unbiased stereological cell counting procedures 
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were used to quantify the number of tyrosine hydroxylase (TH) positive neurons in the 
substantia nigra and to verify the effects of GDNF on dopamine neurons (Fig. 2.4.).  The 
intensity of BrdU labeling in the striatum (Fig. 2.5.A) and the number of BrdU positive 
cells in the dentate gyrus (Fig. 2.5.B) and substantia nigra (Fig. 2.5.C) were counted in 
every sixth section of the whole brain set.  The number of cells double-labeled for BrdU 
and TH was counted in the substantia nigra (Table 2.2.).  The presence of double-labeled 
cells was verified by confocal microscopy. 
While we found a significant increase in the number of dopaminergic neurons in 
the substantia nigra, and increased cell genesis in all of the three areas examined, as 
manifested by nestin and BrdU labeling (Figs. 2.6.-2.8.), none of the new cells were 
labeled with neuronal markers. Thus, with traditional double-labeling ICC and confocal 
microscopy techniques, we did not observe any newly generated dopaminergic neurons in 
the substantia nigra (Figs. 2.9.-2.10.). 
 
Background 
 
TGFα and its receptor 
TGFα is a member of the EGFfamily. It binds to the EGF receptor, a tyrosine 
kinase receptor encoded by the Erb B gene (Todaro et al. 1980). Postnatally, EGF 
receptor continues to be expressed in regions undergoing active neurogenesis including 
the cerebellar granule layer, the SVZ, and the granule layer of the dentate gyrus. In the 
adult rat, EGF receptor expression is restricted to the SVZ and the dentate gyrus (Seroogy 
et al., 1995; Okano et al., 1996; Kornblum et al. 1997; Doetsch et al. 2002).  
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Effects of TGFα on neurogenesis 
With the use of TGFα null mutants (Tropepe et al. 1997; Conover et al. 2000), 
this growth factor was found to be crucial for the full proliferation of stem/progenitor 
cells in the dorsolateral corner of the SVZ and those destined to the olfactory bulb. A 
separate report showed that TGFα null mice had fewer dopaminergic neurons in the 
substantia nigra pars compacta (SNpc) prenatally, suggesting a possible mitogenic role of 
TGFα on the nigrostriatal system (Blum, 1998). 
Fallon et al. (2000) reported that continuous intrastriatal infusion of TGFα alone, 
combined with a 6-OHDA partial lesion, could induce stem cells to proliferate in the 
SVZ, to migrate into the striatum and to differentiate into dopaminergic neurons. A 
normalization of rotation behavior in lesioned rats after TGFα treatment was also 
observed. With or without 6-OHDA lesion, a significant increase in the expression of 
EGF receptor mRNA in the SVZ during drug infusion was observed. With TGFα 
treatment, newly generated dopaminergic neurons, which were double labeled with BrdU 
and dopamine transporter (DAT), were observed in the striatum. This report was the first 
to show evidence of the induction of endogenous neurogenesis in the dopaminergic 
system. Recently, however, Cooper & Isacson (2004) and Frielingsdorf et al. (2004) 
reported independently that they failed to replicate Fallon’s results and found no 
neurogenesis in the basal ganglia. 
Since the addition of new dopaminergic neurons in the adult striatum may 
enhance the nigrostriatal dopaminergic pathway and imply an effective treatment for 
neurodegenerative disease (as we will discuss in later chapters), it is important to follow 
Fallon’s study to confirm the existence of striatal neurogenesis. GDNF is a potent trophic 
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factor for midbrain dopaminergic neurons, so it is reasonable to test the response of 
stem/progenitor cells to the treatment with GDNF in addition to TGFα. 
 
Cell markers 
ICC was used to quantify cell genesis, survival and differentiation. Several cell 
specific markers were used, as described below:  
(1) Markers for stem / progenitor cell: 
It is essential to have unique markers for identifying stem cells in the study of 
neurogenesis. The difficulty lies in that the most primitive cells do not express many 
antigens on the surface or even internally. 
BrdU is a synthetic thymidine analogue, which can only be taken up by cells 
during the S-phase of mitosis, just before mitotic separation, and is a marker of 
proliferating cells and their progeny. 
Nestin is an intermediate filament transiently expressed during neural ontogeny, 
which is first expressed by neuroepithelial cells and radial glia in development, then by 
progenitor cells of the ventricular zone later during the embryonic stage (Lendahl et al., 
1990). In vitro studies show that nestin is only expressed in brain cells with progenitor 
cell qualities. Nestin has been used as the stem cell marker by many groups, and ICC for 
nestin in combination with β-III tubulin can be used to label the neuronal progenitor 
cells. 
(2) Markers for immature cells 
β-III tubulin (commercially known as Tuj-1) is a composite of the microtubules 
expressed very early in the process of neuronal differentiation. It is supposed to have a 
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unique role during early neuronal differentiation and neurite outgrowth, and is used as a 
marker for neuronal-lineaged cells and embryonic neurons immediately postmitotic. 
Microtubule-associated protein-2 (MAP-2) is involved in the microtubule 
reorganization that accompanies neuronal process elaboration. It selectively stains 
neuronal cell bodies and dendrites, serving as a more differentiated neuronal marker than 
β-III tubulin. 
Antibody against NG2 can recognize chondroitin sulphate proteoglycan NG2 on a 
new glial cell type. These cells may morphologically and topographically resemble non-
myelinating oligodendrocytes and/or microglia in the adult CNS (Nishiyama et al. 1999). 
NG2 has recently been used to label immature oligodendrocytes. 
(3) Markers for differentiated cells: 
Glial fibrillary acidic protein (GFAP), an intermediate filament, is commonly 
used as the marker for astrocytes. 
Antibody against oligodendrocytes could be used to label mature 
oligodendrocytes. 
Ox-42 is a CR3 complement receptor; it could be used as a marker for CNS 
microglia. 
NeuN is a transcription factor that is expressed in the nucleus and cytoplasm of 
postmitotic neurons. Enolases are cytoplasmic glycolytic enzymes. The γ-enolase, one 
isoform of the enzyme, is also called neuron specific enolase (NSE) and is expressed only 
in neurons and neuron-derived cells. So both NeuN and NSE can be used as neuronal 
markers. 
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TH catalyzes the reaction converting tyrosine to levo-dopa, the rate-limiting step 
of the neurotransmitter biosynthesis. TH is widely used to stain monoamine-containing 
neurons and as a good marker for dopaminergic neurons in the substantia nigra. DAT 
rapidly takes up extracellular dopamine into presynaptic terminals after dopamine 
release, and is also used as a marker for dopaminergic neurons. 
GABA: a marker for the GABAergic (inhibitory) neurons. 
GAD65/67: Glutamate Acid Decarboxylase (GAD) 65KDa and 67KDa. It is a 
marker that labels CNS GABAergic (inhibitory) neurons. 
It is difficult to determine a cell’s phenotype unequivocally from ICC staining 
because the intensity of labeling varies from cell to cell and the signal-to-noise ratio can 
be low due to variable background staining. Thus, multiple markers were used to classify 
cell types. 
 
Materials and Methods 
 
Animals   
Young adult male Sprague-Dawley rats (Harlan, Indianapolis, IN) were used in 
this study.  All procedures were conducted in the Laboratory Animal Facilities of the 
University of Kentucky, which are fully accredited by the Association for Assessment 
and Accreditation of Laboratory Animal Care International.  The University of 
Kentucky’s Animal Care and Use Committee approved all protocols. 
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Anesthetization 
The animals were anesthetized by chloral hydrate (trichloracetaldehyde 
monohydrate) at the dosage of 300mg/kg body weight. The concentration of the drug 
solution was 0.02g/ml. 
 
Drug continuous infusion 
Rats were randomly divided into three groups (n=9): one group received GDNF, 
another received TGFα, and the third group received aCSF. The table top where the 
experiments were performed, and the stereotaxic instrument, were all disinfected with 
isopropyl alcohol. The scalp of the anesthetized animal was shaved and the animal placed 
in the stereotaxic device. A midline sagittal incision about 2.5 cm long was made using 
sterile instruments and the skull exposed. A subcutaneous pocket in the mid-scapular area 
of the back of the rat was created with a hemostat. Then the Alzet osmotic minipump 
(Durect Corporation, Cupertino, CA; model 2002: 200 µl/14 days) was inserted into the 
subcutaneous pocket, leading the attached catheter to the site for cannula placement. A 
small hole was drilled in the skull over the right frontal cortex and a 5 mm cannula 
attached to the minipump was stereotaxically implanted into the right caudate-putamen 
(coordinates- AP: 1.2mm, ML: -2.7mm) using Bregma as a reference. The pump was 
implanted subcutaneously and the infusate (200µl GDNF or TGFα or aCSF) was 
delivered directly into the striatum at a rate of 0.5µl/hour. The concentration of GDNF 
was 1.5µg/µl and the concentration of TGFα was 0.5µg/µl. After cannula implantation, 
the animal was kept warm on a heating pad until awaking, and then placed back into the 
cage with food and water. It was closely monitored for sign of distress from surgery and 
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anesthesia.  At the 14th day of infusion, the animal was anesthetized and placed back in 
the stereotaxic device. A small incision was made on the back skin and the pump was 
replaced by a new one full of the same infusate (200µl). Altogether, 600µg GDNF or 
200µg TGF was delivered to trophic factor recipients. 
 
BrdU injection 
BrdU (Sigma, St. Louis, MO) was dissolved in 0.9% saline at a concentration of 
200mg/15ml, and sterilized with a 0.2 mm filter. Beginning from the first day of infusion, 
the animal received one i.p. injection of freshly made BrdU per day for five days 
consecutively. The dosage used each time was 200mg/kg. 
 
Tissue collection for infusion studies 
At the end (28th day) of drug infusion, the animal was anesthetized with 
Ketamine and sacrificed by transcardial perfusion of 4% paraformaldehyde. The brain 
was collected and postfixed overnight, and then it was immersed in 30% sucrose for three 
days before slicing on a freezing microtome. Samples were sectioned at a thickness of 
30µm and stored in the cryoprotectant solution at -20°C. 
 
Immunocytochemistry (ICC) 
Free-floating sections stored in cryoprotectant were used. They were rinsed in 
0.1M PBS, immersed in 0.3% H2O2, and blocked by 4% normal goat serum with 0.4% 
Triton X-100 in PBS before primary antibody incubation for one to two days. Primary 
antibodies generated in mouse, rat, rabbit recognizing the following antigens were used: 
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mouse anti-nestin (Rat401; 1:20, Developmental Studies Hybridoma Bank, Iowa City, 
IA), mouse anti-β-III tubulin (Tuj-1; 1:1,000, Covance, Berkeley, CA), mouse anti-
neuronal nuclear antigen (NeuN; 1:500, Chemicon), mouse anti-TH (1:1,500, Chemicon), 
mouse anti- GFAP (1:1,000, Chemicon), mouse anti-NG2 (1: 200, Chemicon), mouse 
anti-MAP2 (1:200, Chemicon), mouse anti-GABA (1:200, Chemicon), rat anti-DAT 
(1:5,000, Chemicon), rabbit anti-tyrosine hydroxylase (TH; 1:2,500, Pel-freeze, Pogers, 
AR), and mouse anti-OX42 (1:4,000, BD PharMingen, San Diego, CA). The sections 
were then rinsed in PBS and incubated in biotinylated secondary antibodies. The antigens 
were visualized by using ABC solution (ABC standard kit, Vector) followed by 
diaminobenzidine (DAB)-peroxidase histochemistry. 
For BrdU ICC, rat anti-BrdU (1:200, Accurate Chemical, Westbury, NY) was 
used. Pretreatments were needed before the incubation of the primary antibody. DNA 
was denatured by 50% formamide in 2×SSC for two hours at 65°C, and then the sections 
were rinsed in 2×SSC, and incubated in 2N HCl at 37°C for 30 minutes. After being 
rinsed in PBS, sections were then immersed in 0.1M boric acid (pH 8.5) for 10 minutes, 
followed by a rinse in PBS. 
 
Bioquant 
The Bioquant Image Analysis System was used to quantify dopaminergic neurons 
in the substantia nigra and the newly generated cells in certain brain areas. 
The number of TH-positive neurons in the SNpc was estimated using an optical 
fractionator method for unbiased stereological cell counting (West et al., 1991; West 
1993; Harding et al., 1994).  With a random selection of the first section, every sixth 
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section thereafter was sampled through the entire SNpc, which entailed the analysis of 
seven to ten sections per animal.  The average section thickness was 14 µm, as 
determined from measuring mounted sections from each animal.  The SNpc was defined 
as consisting of all midbrain TH-positive neurons except those interspersed with the 
oculomotor nerve rootlets.  On each section, a 120µm × 120µm grid was superimposed, 
with an 80µm × 80µm counting chamber placed on each grid.  All of the TH-positive 
neurons with clearly identified nuclei were counted, if they were either completely within 
the boundaries of the dissector box or crossing the upper or right side of the box within 
its 14-µm-depth.  This resulted in up to 719 TH-positive cells counted per side per 
animal.  The estimated total number of TH-positive neurons in the substantia nigra was 
calculated based on the following formula: N = ΣQ- x 1/ssf x 1/asf x t/h (West et al., 
1991) where N is the estimate of the total number of cells, ΣQ- is the number of counted 
cells on the sampled sections through the substantia nigra, ssf is the section sampling 
fraction, asf is the area sampling fraction.  For t/h, t is the actual section thickness and h 
is the height of the dissector box. 
The areas being investigated for BrdU labeling include the caudate-putamen, the 
dentate gyrus of the hippocampus, and the substantia nigra. One in every 6th of the whole 
brain sections was used. The sections used for counting cells in the striatum were labeled 
with BrdU and counter-stained with neutral red. The sections from the hippocampus were 
double labeled with BrdU and NeuN, and those from the substantia nigra were double 
labeled with BrdU and TH. The area (number of pixels) of the regions was quantified. 
The number of BrdU-positive cells in each region was estimated. On each section, a 
300µm×300µm grid was superimposed with a 300µm×300µm counting chamber placed 
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on each intersection. All cells completely within the boundaries of the chamber or 
crossing the upper or right side of the chamber were counted. 
The total number of BrdU+/TH+ double-labeled neurons was counted on every 
sixth section containing the substantia nigra.  Similarly, the number of BrdU+/NeuN+ 
neurons was counted in the granule cell layer of the dentate gyrus of every sixth section.   
 
Statistical analysis 
The results are expressed as means ± SEM. Statistical significance in each side 
between the treatment groups was assessed using two-way analysis of variance 
(ANOVA) with side as within-subjects repeated factor and treatment as the between-
subjects factor. Subsequantly, the effect of GDNF treatment was assessed for each side 
separately by two-tailed Student’s t-tests for independent samples. Unequal variance was 
assumed. The differences in the number of BrdU+ or TH+ cells in the striatum and the 
substantia nigra between the vehicle-treated group and the GDNF-treated group were 
analyzed. For BrdU immunoreactivity in the dentate gyrus, the number of BrdU labeled 
cell were quantified, and the length of each corresponding dentate gyrus was also 
measured. The average number of BrdU+ cells in each 100µm-long segment of the 
dentate gyrus was calculated for each section and averaged in each side. The results were 
compared between the two treatment groups and presented.  
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Immunofluorescent Staining  
Free-floating sections stored in cryoprotectant solution were used. For fluorescent 
double-labeling, they were first pre-treated, blocked by 4% normal goat serum, and 
incubated in anti-BrdU primary antibody (as described above) for 48 hours, and rinsed 
thoroughly and incubated with Alexa Fluor 568 goat anti-rat antibody (1:500, Molecular 
Probes, Eugene, OR) for one hour. After being rinsed in PBS, the sections were blocked 
by 4% normal goat serum again before being incubated in another primary antibody (as 
listed above) for one to two days. Corresponding to the source of the primary antibody 
applied, Alexa Fluor 488 secondary antibody was used following complete rinsing in 
PBS. Fluorescent sections were evaluated using Leica TCS laser scanning confocal 
microscope systems (Am Friedensplatz, Mannheim, Germany). 
 
Results 
 
GDNF labeling 
In coronal sections through the region of the striatum containing the catheter, the 
entire hemisphere of the brain was filled with GDNF in the GDNF recipients.  In addition 
to the striatum, corpus callosum and cortex, this included the right lateral ventricle, 
suggesting that significant levels of GDNF could have been transported through the CSF.  
Periventricular GDNF ICC staining was evident through the full extent of the right lateral 
ventricle and the third ventricle.  Some GDNF staining was evident around the 
ventricular borders of the right hippocampus (Fig. 2.3A).  Retrograde transport of GDNF 
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was evident in the right substantia nigra, with many neurons displaying GDNF+ staining 
(Fig. 2.3B, C).   
The left hemisphere of the brain was not heavily immunostained for GDNF.  
Some GDNF immunostaining was present in the contralateral septum, midline cortex and 
left hypothalamus adjacent to the third ventricle.  However, GDNF+ staining was not 
seen in the left substantia nigra.  The left hippocampus was mostly devoid of GDNF 
immunostaining.  
 
Nestin labeling in the brain 
Nestin staining was observed in all of the treatment groups in several brain 
regions, including the areas lining the lateral ventricle and around the catheter site (Fig. 
2.7.). It was also extensive in the hippocampus (Fig. 2.8.). 
TGFα recipients had the most extensive nestin immunoreactivity. There was a 
massive stem/progenitor cell proliferation in the SVZ shown by the increased volume of 
nestin staining along the lateral ventricle, especially on the infusion side. There was also 
an S-shaped ridge of cells stained with nestin that originated from the ipsilateral dorsal 
SVZ, migrated through the corpus callosum, and projected toward the infusion site. All 
these results were in consistence with those reported by Fallon’s group (2000). 
When compared with the aCSF (vehicle) treated group, the GDNF recipients had 
higher intensity of nestin staining in both the SVZ (Fig. 2.7.) and the hippocampus (Fig. 
2.8). 
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By using double labeling immunofluorescent staining, it was confirmed that a 
high percentage of the nestin positive cells were stem/progenitor cells that incorporated 
BrdU as well (Fig. 2.6.). 
 
TH labeling in the substantia nigra 
Quantitative cell counting showed a significant increase in TH+ neurons in the 
right substantia nigra of GDNF recipients (Fig. 2.4).  The average number of 
immunopositive neurons per animal was increased in the right nigra by over 30%, from 
7010 ± 398 (s.e.m.) in vehicle recipients to 9249 ± 619 in the rats receiving GDNF. 
 
BrdU labeling in the striatum, hippocampus and substantia nigra 
The GDNF recipients had a significantly higher number of BrdU labeled cells in 
the contralateral striatum (Fig. 2.5.A). There is concern that cannula implantation by 
itself could cause a local cell response and increase the number of BrdU+ cells. Our 
experience to date is that catheter placement into the brain results in only a mild, 
localized tissue response (Ai et al., 2003; Grondin et al., 2003).  As animals from the 
control group underwent the same procedures, there is an internal control to exclude the 
treatment effect.  
GDNF significantly increased the number of BrdU+ cells bilaterally in both the 
hippocampus (Fig. 2.5.B) and substantia nigra (Fig. 2.5.C).  The number of BrdU positive 
cells in each 100µm-long segment of dentate gyrus in GDNF recipients was increased by 
~78%, compared to vehicle controls.  The increase was not as great in the substantia 
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nigra, where the number of BrdU+ cells was ~52% larger in the substantia nigra of the 
trophic factor recipients.   
 
Existence of neurogenesis with traditional double-labeling ICC 
By the use of light microscope double-labeling with BrdU and a neuronal marker 
(NeuN, or NSE, or TH), we evaluated the existence and extent of neurogenesis in the 
three brain regions. Co-labeling of BrdU with NeuN/NSE was observed in the dentate 
gyrus of the hippocampus, but not in the striatum and the substantia nigra (Fig. 2.10.). An 
additional search for BrdU+/TH+ cells in the substantia nigra (Fig. 2.9.) was conducted 
by counting every BrdU+ cell in every 6th section through the rostral caudal extent of the 
substantia nigra.  While 1549 BrdU+ cells were counted in the 18 rats (controls and 
GDNF-treated) used in this study, none were TH+ (Table 2.2.).  
 
Existence of neurogenesis with immunofluorescent study 
Selected sections were also evaluated by double-label confocal microscopy for 
other cell markers (Table 2.1) to determine if any of the BrdU+ cells co-labeled with 
specific antigens for GABAergic neurons, immature neurons, oligodendroglia, astocytes 
or microglia.  
While there were many BrdU+ cells identified in the striatum and substantia nigra 
of both vehicle and GDNF recipients, none were TH+ (Fig. 2.10 A-C).  In contrast to the 
striatum and substantia nigra, BrdU+ granule cells were seen in the hippocampus (Fig. 
2.10. D-F). A high percentage of BrdU+ cells were also found to be labeled with nestin. 
This confirmed that our procedures were labeling stem cells in the brain. 
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With the exception of BrdU+/Nestin+ cells in the SVZ and BrdU+/NeuN+ cells in 
the dentate gyrus, no double-labeled cells were found in this survey in any of the 
treatment groups. The TGFα treatment, which followed the procedures used by Fallon’s 
group with only minor modifications, failed to induce the striatal neurogenesis as 
reported in their publication. Our results were consistent with the recent report (Cooper & 
Isacson, 2004). 
 
Discussion 
The present results demonstrated that stem/progenitor cells existed locally within 
the SVZ, the dentate gyrus and the substantia nigra. 
Our experiments with TGFα continuous infusion failed to replicate the profound 
effects of this trophic factor on stem cell differentiation in the basal ganglia reported by 
Fallon et al (2000). Since the publication, there has been no report that could duplicate 
their results with TGFα treatment. In fact, two separate research groups from Harvard 
University in the United States and Lund University in Sweden (Cooper & Isacson, 2004; 
Frielingsdorf et al. 2004) have challenged the conclusion. Independently, they repeated 
Fallon’s experiments with small modifications and found no evidence of any 
dopaminergic neurogenesis in the nigrostriatal system in any treatment group. It is fair to 
say that neurogenesis is rare, if present at all, in the nigrostriatal system following 
intrastriatal TGFα infusion. 
Although the proliferation of stem/progenitor cells could be induced or enhanced 
by GDNF continuous striatal infusion, they do not necessarily undergo further 
differentiation into functional neurons. This holds true in the substantia nigra at least four 
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weeks after the start of GDNF treatment. Since we observed a significant increase in the 
number of dopaminergic neurons in the ipsilateral SNpc, we speculate that GDNF may 
have either increased TH immunoreactivity of existing dopaminergic neurons, or induced 
Gliogenesis, thus indirectly influencing dopaminergic neurons. At this time, we could not 
rule out the possibility that GDNF may activate neurogenesis in response to 
injury/damage. We designed and carried out studies on two different Parkinsonian rat 
models under the treatment of GDNF in Chapters 4 and 5. 
Neurogenesis in the dentate gyrus was confirmed by confocal microscopy with 
BrdU and NeuN. There was a significant increase of BrdU positive cells in both sides of 
the dentate gyrus under GDNF treatment. It has been reported that newly generated 
neurons in mouse hippocampus mature into functional granule cells (van Praag et al. 
2002) and that a reduction in neurogenesis coincides with impaired learning and memory 
of the hippocampal-dependent tasks (Shors et al. 2001). Pelleymounter et al (1999) 
reported that i.c.v. administration of GDNF improved spatial learning in aged rats. It was 
reasonable to speculate that GDNF might increase neurogenesis in the hippocampus 
under normal conditions, thus playing an important role in learning and memory. To test 
this hypothesis, it is important to see whether this kind of stem cell proliferation and 
differentiation could be linked to the improvement in behavioral tests on cognition. 
Furthermore, the issue of whether the newly generated neurons contributed directly to 
improved learning and memory needs to be addressed. 
Since BrdU positive cells hardly express any of the cell markers tested in this 
experiment, it is important to identify the phenotype of these cells with their 
ultrastructure characteristics, which we observed in the next chapter. 
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Several other points of discussion are clarified below: 
 
Anesthetization 
Chloral hydrate is an anesthetizing drug commonly used in the literature on 
animals before surgery.  With proper dosage (300mg/kg BW) and concentration 
(0.02g/ml), its use in our lab has been found to be safe and effective.  Typically, it 
provides stable anesthesia in rats for at least an hour, which is an adequate time period for 
our surgeries.  The concentration of chloral hydrate is critical based on the literature and 
our own experience.  When the concentration of solution used is higher than 50 mg/ml, it 
can cause problems such as adynamic ileus (Fleischman et al. 1977) and peritonitis in 
rats.  On the other hand, chloral hydrate solution at a concentration as low as 20 mg/ml 
does not cause these problems, nor does it typically induce perceptible stress in rats. 
Two other commonly used anesthetic drugs, Ketamine and Pentobarbital, were 
not chosen for survival surgeries in our studies.  This is because both of the drugs have 
been shown to change the dopamine release in the brain, thereby interfering with our 
observation in the dopamine system. 
 
The limitation of cell markers 
A lot of controversy has been raised about the use of BrdU as a stem/progenitor 
cell marker based on the fact that BrdU could also be incorporated into the DNA strand 
during repair process or in cells undergoing apoptosis (Nowakowski & Hayes, 2000; 
2002). Another point is that the permanent replacement of thymidine by BrdU on the 
DNA strand causes cumulative mutations in rapidly expanding cell populations. 
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Depending on the number of divisions a stem/progenitor cell undergoes before 
differentiation, the severity of this effect on newly generated cells is varied. If the 
mutation occurred at an earlier stage of stem cell proliferation, then the mutation could be 
expected in a higher number of neuronal offspring. On the other hand, the BrdU labeling 
probably underestimates the number of newly generated cells because BrdU is only 
available for nuclear incorporation for a few hours after treatment. 
Nestin is widely used as a stem cell marker (Lendahl et al., 1990). However, all 
commercially available antibodies against nestin have a cross-reaction with an 
endothelial antigen (Palmer et al. 2000). The nestin antibody may also stain for 
ependymal cells (Garcia-Verdugo et al., 1998) and for radial glial cells in the developing 
rat CNS. Thus, it might be hard to discriminate the stem/progenitor cells unequivocally. 
If the same cells were stained with both BrdU- and nestin- antibodies, there is 
reasonable confidence that they are in fact stem cells. 
Ox-42 could serve as a microglia marker. However, antibody against ox-42 could 
label most macrophages, dendritic cells, and granulocytes as well.  
In this study, we did confocal immunofluorescent staining for both BrdU and 
nestin on brain sections. A high percentage of BrdU positive cells along the lateral 
ventricle were also stained with nestin; thus, they could be identified as stem cells. 
It has been argued that each of the neuronal markers has its disadvantages. NeuN 
is generally accepted to be neuron specific, but it can also label other cell types including 
cells from the adrenal gland and the intermediate lobe of the pituitary gland (Mullen et 
al., 1992). NSE can label not only neurons but also astrocytes and oligodendrocytes 
(Deloulme et al., 1996; Sensenbrenner et al., 1997). MAP-2 labels EGF-responsive 
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precursor cells, a possible stage of astroglial development (Rosser et al. 1997). In this and 
the following experiments, we used NeuN, NSE and MAP-2 to label neurons. The 
expression of at least two antigens in a population of adult generated cells is a good 
indicator of new neurons. 
Similarly, both TH and DAT were used to label dopaminergic neurons. In our 
study, no cell in the nigrostriatal pathway was observed as double-labeled with BrdU and 
TH/DAT, confirmed the lack of newly generated dopaminergic neurons. 
 
Bilateral effects of GDNF on stem/progenitor cell proliferation 
In our experiments, we observed that unilateral delivery of GDNF into the 
striatum induced stem/progenitor cell proliferation in both sides of the hippocampus and 
substantia nigra. This was shown by increased intensity of nestin staining and quantity of 
BrdU labeled cells in these regions. Although it is hard to compare the number of striatal 
stem/progenitor cells on the infusion side due to the catheter implantation interference, 
the BrdU labeling of the contralateral striatum increased significantly in the GDNF 
recipients when compared to the vehicle recipients. All of these results suggest that 
unilateral infusion of GDNF may have bilateral effects on stem/progenitor cell 
proliferation. 
This is not surprising, given the evidence that GDNF might be carried by CSF in 
the brain and exert its function on both hemispheres (Fig. 2.3.A). Besides, GDNF 
delivered to the striatum could be retrogradely transported and/or diffused back to the 
substantia nigra (Tomac et al. 1995; Kordower et al. 2000). Thus, a unilateral delivery of 
GDNF may affect both of the brain hemispheres. 
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This observation is consistent with our previous reports in rhesus monkeys (Gash 
et al. 1996; Grondin et al. 2002; Grondin et al. 2003). A chronic unilateral i.c.v. infusion 
of 7.5µg GDNF per day for two months, for example, induced bilateral increases of the 
stimulus-evoked release of dopamine and the basal extracellular levels of dopamine in the 
substantia nigra of aged rhesus monkeys (Grondin et al. 2003). 
 
The identity of the BrdU positive cells 
The co-localization of BrdU and nestin in the SVZ in all of the animals confirmed 
the existence of endogenous adult stem/progenitor cells (Fig. 2.6.). 
Most of the detected BrdU positive cells in the striatum, hippocampus, and the 
substantia nigra (Fig. 2.10 A, B, C) did not express any of the cell markers we used in the 
immunofluorescent study. There were instances where a BrdU+ nucleus was closely 
juxtaposed to a TH+ cell body and could have been mistakenly counted as a positively 
labeled neuron.  In each instance, closer examination of confocal microscopy revealed 
that the neuronal nucleus was not BrdU+.  In contrast to the striatum and substantia nigra, 
BrdU+ granule cells were seen in the dentate gyrus of the hippocampus (Fig. 2.10.D.-F.), 
showing that the procedures could label at least some neurons. 
The lack of co-localization of BrdU and other cell markers might be due to 
several of the reasons listed below. First, it could be that a BrdU positive cell expresses a 
cell marker that was not yet used. Second, the cell might be a progenitor cell not yet 
committed to any certain lineage or expressing any specific marker. Third, it might be a 
quiescent cell during development. Last, the cell may remain as an adult stem cell. These 
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possibilities were addressed using electron microscopy to observe the ultrastructure and 
identify the phenotype of these BrdU positive cells. 
The absence of any BrdU+/TH+ cells in the substantia nigra in our studies 
suggests at least two possibilities: 
(a)  that our procedures are not effectively labeling newly generated dopaminergic 
neurons in the  basal ganglia. 
(b)  that new dopamine neurons are not generated under the conditions of our 
studies. 
Evidence for (a) comes from Zhao et al. (2003), who reported that repeated i.p. 
injections labeled less than one nigral BrdU+/ TH+ cell per mouse, while 22 cells/animal 
were labeled using long term i.c.v. BrdU infusion.  (b) The possibility that new dopamine 
neurons are not generated in the adult basal ganglia under the conditions in our 
experiments, which is consistent with the findings of Lie et al. (2002) in the rat. While 
there were progenitor cells in the adult substantia nigra, they did not differentiate into 
dopaminergic neurons in normal and 6-OHDA lesioned animals. The absence of 
neurogenesis in the adult basal ganglia is also consistent with the observations from many 
groups that neurogenesis in adult mammals is limited to granule cells in the hippocampus 
and the olfactory bulb (for a critical review, see Rakic, 2002).  
Our next study (Chapter 3) delivered BrdU through i.c.v. infusion and compared 
the effectiveness of our labeling with the repeated BrdU i.p. injections. Later on 
(Chapters 4, 5), we tested whether injury, in combination with GDNF treatment, might 
serve as a positive signal for neurogenesis in the substantia nigra.  
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Table 2.1 – Antibodies used in study 
Antibody 
to Host/Type Dilution Company Cell Type Immunostained 
BrdU Rat monoclonal 1:200 Accurate 
Stem cells and their progeny; 
Cells undergoing DNA repair 
GABA Mouse monoclonal 1:50 Chemicon 
GAD65/67 
Mouse 
monoclonal 1:200 Chemicon 
GABAergic neurons 
GDNF Goat polyclonal 1:200 
R & D 
Systems Cells with GDNF labeling 
GFAP Mouse monoclonal 1:1,000 Chemicon Astrocytes 
MAP2 Mouse monoclonal 1:200 Chemicon Neurons 
Nestin 
(Rat401) 
Mouse 
monoclonal 1:20 DSHB Neuroepithelial stem cells 
NeuN Mouse monoclonal 1:500 Chemicon Neurons 
NG2 Mouse monoclonal 1:200 Chemicon Immature Oligodendrocytes 
Oligoden
-drocyte 
Mouse 
monoclonal 1:5,000 Chemicon Oligodendrocytess 
Ox-42 Mouse monoclonal 1:4,000 
BD-
Pharmingen Microglia 
TH Mouse monoclonal 1:1,500 Chemicon 
TH Rabbit polyclonal 1:3,000 Pel-freeze 
Cells, including dopamine 
neurons, containing tyrosine 
hydroxylase 
β-III 
tubulin 
(Tuj-1) 
Mouse 
monoclonal 1:1,000 Covance 
Early postmitotic embryonic 
neurons  
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Table 2.2 - BrdU+ cell counts in the substantia nigra. Every 6th section through the 
midbrain in each animal was used for cell counting. The number of BrdU+ cells was 
counted in the substantia nigra on each side of each animal. The total number of BrdU+ 
cells in each treatment group was summed in this table. Although altogether  
1, 549 cells were observed with BrdU immunoreactivity, no BrdU+/TH+ double labeled 
cell was observed in each area.  
 
Right Side Left Side 
Vehicle GDNF Vehicle GDNF 
0 0 0 0 
Substantia Nigra 
BrdU+/TH+ neurons 
BrdU+/TH- cells 310 500 304 435 
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L: Left; LV: Lateral Ventricle; R: Right; STR: Striatum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 – Illustration of osmotic pump implantation. The osmotic pump filled with 
infusate (200 µl GDNF or TGFα or aCSF) was implanted subcutaneously and the 
infusate was delivered directly into the striatum at a rate of 0.5µl/hour. The 
concentration of the GDNF was 300µg/200µl, the concentration of TGFα was 
100µg/200µl. At the 14th day of infusion, the animal was anesthetized and placed 
back in the stereotaxic device. A small incision was made on the back skin and the 
pump was replaced by a new one full of the same infusate (200µl). 
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Figure 2.2 – Stem cells in culture express a series of markers as they differentiate and 
commit to either neuronal or glial lineages.  
Figure modified from Palmer et al. 1997. 
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Figure 2.3 – GDNF labeling. A. GDNF immunostaining along the ventricular wall 
(arrows), indicating that the trophic factor had entered the cerebrospinal fluid (CSF).  
Note the intense labeling of the habenula (HB).  Faint GDNF immunoreactivity was 
evident in the hippocampus.  A large blood vessel (arrowhead) runs from the thalamus 
to the ventricular wall. Scale bar = 200µm.  B.  GDNF immunostaining in cells in the 
substantia nigra (SN) on the right side showed retrograde transport from the striatum.  
In contrast, retrograde transport was restricted to the side of infusion with none of the 
cells in the contralateral SN (SN*) displaying immunoreactive GDNF.  Scale bar 
=1mm.  C.  A higher power magnification of neurons in the SN staining for GDNF 
(inset from B).  Scale bar = 50µm.  
 
3V: third ventricle; DG: dentate gyrus; CA3: field CA3 of hippocampus 
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Figure 2.4 – The number of TH labeled cells in the substantia nigra. GDNF-
treated animals have higher number of TH immunoreactive cells in both 
hemispheres than the vehicle recipients. But the difference was significant 
only on the infusion side. (**: P<0.01) 
Right side: F=9.248, P=0.008; Left side: F=1.772, P=0.202. 
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Figure 2.5A – Bioquant cell counting of BrdU labeled cells in the striatum. BrdU 
labeled cells from 1 in every 6th whole brain sections in the striatum of each animal 
were screened and counted. There was a significantly higher number of BrdU 
labeling in the contralateral side with GDNF treatment than with vehicle treatment.  
(*: P<0.05) 
Right side: F=0.792, P=0.388; Left side: F=4.849, P=0.044. 
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Figure 2.5B – Bioquant cell counting of BrdU labeled cells in the dentate gyrus. 
BrdU labeled cells from 1 in every 6th whole brain sections in the dentate gyrus of 
each animal were screened and counted. The length of each corresponding dentate 
gyrus was also measured. The average number of BrdU-positive cells in each 100µm-
long segment of the dentate gyrus was calculated for each section and averaged in 
each side of the drug treatment groups, as shown above. There was significantly 
higher number of BrdU labeled cells in both sides of the dentate gyrus with GDNF 
treatment than with vehicle treatment.  (**: P<0.01) 
Right side: F=9.193, P=0.008; Left side: F=9.141, P=0.008. 
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Figure 2.5C – Bioquant cell counting of BrdU labeled cells in the substantia 
nigra. Number of BrdU labeled cells in the substantia nigra of GDNF-treated 
animals was significantly higher in both hemispheres than that in the vehicle 
recipients. (*: P<0.05). 
Right side: F=6.495, P=0.021; Left side: F=4.744, P=0.045. 
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LV: Lateral ventricle 
 
 Figure 2.6 – Confocal microscopy was used to confirm the identity of nestin+ 
cells. Cells in the subventricular zone were stained with nestin (in green, shown 
in A) and BrdU (in red, shown in B). The two markers were found co-localized 
(in yellow, shown in C) in many of those cells (arrowheads). This demonstrated 
a correlation between nestin immunoreactivity and stem cell proliferation. 
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CPu: Caudate-Putamen; LV: Lateral Ventricle; gcc: Genu Corpus Callosum
Figure 2.7 – Nestin immunoreactivity in the forebrain. Nestin labeling was found in the 
subventricular zone (arrows) around the lateral ventricle (LV) in both the vehicle-treated 
animals (A) and GDNF-treated animals (B). The nestin positive fibers also extended 
(arrowheads) into the striatum in both groups. The intensity of nestin staining was 
higher in these locations after GDNF treatment. Nestin immunoreactivity was also found 
around the catheter site (*) in the caudate-putamen (CPu), but most of these cells were 
microglial cells, not stem cells. Gcc: genu of corpus callosum. 
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D3V: Third Ventricle; LV: Lateral Ventricle 
 
 
 
 
Figure 2.8 – Nestin immunoreactivity in the hippocampus. Nestin was also expressed in 
the hippocampus in both the vehicle recipients (A, C) and GDNF recipients (B, D). 
Again, the nestin immunoreactivity was much stronger in the GDNF treated group, 
suggesting higher stem cell proliferation in the hippocampus, where neurogenesis has 
been demonstrated by many investigators to be active in adulthood. 
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Figure 2.9 – No evidence of neurogenesis in the substantia nigra was observed with 
traditional double-labeling ICC. ICC for BrdU and TH was conducted in tissue sections 
containing the substantia nigra to determine the number of cells co-labeling for both 
markers. TH is a marker for dopaminergic neurons. BrdU positive cells were stained 
black (arrowheads) and the brown cells were stained with TH (arrows). There were no 
neurons identified that unequivocally were labeled with both markers. 
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Figure 2.10 – Evidence of neurogenesis in the substantia nigra and hippocampus 
observed with confocal microscopy. Confocal microscope images illustrating double 
immunoflourescence staining of BudU and either TH in the substantial nigra (A-C) or 
NeuN in the dentate gyrus (D-F) of the BrdU treated rats.  A-C. A large number of 
cells (green) in the substantia nigra were immunostained with TH and a few labeled 
with BrdU (red).  No double labeled cells were found.  D-F. In the hippocampal 
dentate gyrus, neurons were stained with NeuN (green) and a few of them were double 
labeled (yellow) with BrdU (red). 
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Chapter Three 
 
Morphology of BrdU Positive Clls in the Striatum,  
Dentate Gyrus and Substantia Nigra in Normal Animals  
with Continuous i.c.v. Infusion of BrdU 
 
Summary 
 
From our previous study, GDNF has been shown to promote cell genesis in 
various brain regions including the striatum, hippocampus and substantia nigra. While 
cells double-labeled for NeuN and BrdU were identified in the dentate gyrus of the 
hippocampus, no double-labeled neurons were found in the striatum and substantia nigra 
(Fig. 3.1.).  Furthermore, double-label studies using confocal evaluation of BrdU labeled 
cells for other cell markers (Table 2.1.) were negative.  Therefore, the current study was 
designed to characterize the morphological features of BrdU labeled cells in the striatum, 
dentate gyrus and substantia nigra at the electron microscopic level.  Six rats received 
direct infusion of 150 mg/ml BrdU in dimethyl sulfoxide (DMSO) into the right lateral 
ventricle for 28 days, following procedures detailed elsewhere (Zhao et al., 2003).  The 
animals were then euthanized and the substantia nigra region of the brain processed for 
electron microscopic ICC.  Cell features, cell size and nuclear size of the first eight-ten 
BrdU positive cells identified in the dentate gyrus (Fig. 3.2.) and substantia nigra (Fig. 
3.3) region of each animal were evaluated.    
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Background 
 
BrdU infusion vs. BrdU injection 
The route and duration of delivery of BrdU appear to be very important in the 
report by Zhao et al. (2003). When comparing the two different routes of BrdU delivery 
for two days, one through continuous i.c.v. infusion and the other through repeated i.p. 
injections, they observed a 5-fold higher number of BrdU labeled cells in the dentate 
gyrus and the substantia nigra with BrdU i.c.v. infusion. While the authors observed only 
one BrdU+/TH+ cell in five mice five weeks after a single i.p. injection of BrdU, an 
average of 22 newly generated dopaminergic neurons were observed in the substantia 
nigra in two mice treated with BrdU continuous i.c.v. infusion for 21 days. Since our 
study was carried out with BrdU repeated i.p. injection similar to theirs, this raised a 
question of the effectiveness of our technique in identifying stem cells and their progeny. 
Thus, we tested the existence and extent of neurogenesis with BrdU continuous infusion 
with similar dosage and duration to the previous report. Most recently, Zhao’s methods 
were repeated and the results challenged by Frielingsdorf et al (2004). 
 
The advantage of 3,3’,5,5’-tetramethylbenzidine (TMB) as a chromogen in detecting 
BrdU labeling 
The chromogen TMB is used for pre-embedding ICC to visualize BrdU labeled 
cells. As a noncarcinogenic analog of benzidine, it is routinely used as the key substrate 
for enzyme immunoassays involving horseradish peroxidase tagged antibodies. In our 
experiments, it develops a deep blue color in the presence of peroxidase. 
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This chromogen has the advantage of being higher performing and more sensitive 
than the other peroxidase chromogens (Rye et al. 1984).  
In this particular study, the antigen BrdU presents inside the nucleus. The BrdU 
staining with DAB as a chromogen would have very similar appearance as chromatins in 
the nucleus, thus giving us false positive signals. On the other hand, the BrdU staining 
with TMB has a crystallized appearance, providing us with a satisfactory way to identify 
the antigen unambiguously and confidently.  
 
Materials and Methods 
 
Animals   
Animals used here have the same characteristics as described in the first study. 
 
BrdU infusion 
Altogether ten animals were used for a BrdU infusion study. The animals were 
anesthetized with chloral hydrate (300mg/kg, i.p.), and a 3.5 mm cannula attached to the 
Alzet osmotic minipump (Durect corporation, Cupertino, CA; model 2004: 200µl/28 
days), which was stereotaxically implanted into the right lateral ventricle (coordinates-  
AP: -0.9mm, ML: -1.4mm) using Bregma as a reference. The pump was implanted 
subcutaneously and the infusate (200µl BrdU solution) was delivered directly into the 
lateral ventricle at a rate of 0.25µl/hour. The concentration of the BrdU solution was 
150mg/ml in dimethyl sulfoxide (DMSO). 
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Electron microscopy 
Among the animals that received BrdU continuous infusion, six animals were 
used for electron microscopy. At the end of BrdU infusion, animals were transcardially 
perfused by a fixative consisting of 4% paraformaldehyde and 0.2-0.5% glutaraldehyde. 
The brains were collected and postfixed overnight with 4% paraformaldehyde only, and 
then cut into 50µm sections on a vibratome. First, sections were stained for BrdU using 
TMB as a chromogen. The process of BrdU labeling was the same as described above 
with the exception that, instead of visualizing the avidin-biotin-HRP complex with DAB, 
TMB was used as a chromogen. Reaction in TMB was based on the protocols of Oloucha 
(1985) and Henry (1985) with minor modifications. Briefly, the sections were removed 
from the ABC solution and rinsed three times in 0.1M phosphate buffer (pH 6.0). Then 
the sections were incubated in the TMB solution consisting of 48.75ml of 0.25% 
molybdic acid in 0.1M phosphate buffer, pH6.0 and 2.5mg TMB in 1.25ml pure EtOH 
for 20 minutes. 0.5 ml of 0.3% hydrogen peroxide was then added to this solution 
containing the sections. When labeling was observed, the sections were removed and 
rinsed in Tris buffer, pH7.4, for one minute. The TMB reaction product was stabilized in 
a DAB/Cobalt/H2O2 reaction solution (consisting of 0.05% DAB, 0.025% cobalt 
chloride, and 0.001% H2O2 in Tris Buffer, pH7.4). As soon as the product turned blue-
black, the reaction was stopped by rinsing the sections in 0.1M phosphate buffer, pH7.3. 
After the sections were rinsed twice in 0.1M phosphate buffer, they were post-fixed in 
1% osmium, rinsed, dehydrated and embedded in Spurr’s electron microscopy resin. To 
identify individual cell types with BrdU labeling in the striatum and substantia nigra, 
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ultrathin (90 nm) sections were cut with a diamond knife, stained with lead citrate and 
examined under an electron microscope. 
 
Immunofluorescent staining  
Four animals were used for an immunofluorescence study. All of the procedures 
used were the same as described in the earlier study.  
 
Results 
 
No evidence of neurogenesis was observed in the substantia nigra 
Selected sections from the substantia nigra were evaluated by double-label 
confocal microscopy for other cell markers (Table 2.1.) to determine if any of the BrdU+ 
cells co-labeled with specific antigens for GABAergic neurons, immature neurons, 
oligodendroglia, astocytes or microglia.  
Although there is a higher number of BrdU+ cells throughout the brain with BrdU 
continuous i.c.v. infusion as opposed to BrdU repeated i.p. injections, no double-labeled 
cells were found in the substantia nigra (Fig. 3.1).   
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The phenotype of BrdU labeled cells in different areas of the brain under the electron 
microscope  
Altogether seventy two BrdU+ cells from the hippocampus and fifty BrdU labeled 
cells from the substantia nigra were characterized in the six animals receiving continuous 
intraventricular BrdU infusion for 28 days (Fig. 3.2.). 
Of the 72 BrdU labeled cells from the hippocampus observed, 24 were very close 
to the basal lamina (Fig. 3.2.C); 17 were close to a neuron (Fig. 3.2.A) and 29 appeared 
to be solitary cells (Fig. 3.2.B). A majority of the cells (89%) possessed rounded nuclei 
with very little cytoplasm. The average size of the nucleus is 19µm2 while the biggest 
nucleus encountered had an area of about 47µm2. 
Among the 50 cells from the substantia nigra, eight were small paired cells 
(couplets, Fig. 3.3. A), 12 were satellite cells to much larger cells (Fig. 3.3. B) and 30 
appeared to be solitary cells.  Most of the cells (84%) possessed rounded nuclei, with 
irregular nuclei (Fig. 3.3. C) found in a minority (16%) of the cells.  All were small cells 
consisting of a nucleus surrounded by a thin rim of cytoplasm. The average area of a cell 
with a rounded nucleus was 18 µm2, of which the nucleus occupied 16 µm2. Cells with 
irregular nuclei were even smaller, with an average total area of 14 µm2, most of which 
taken by the nucleus with an area of 12 µm2.  On average, the cytoplasm accounted for 
around 13% of the cellular area.   
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Discussion 
As opposed to the extensive neurogenesis reported by Zhao et al (2003), our 
results did not show evidence of newly generated neurons even after continuous BrdU 
infusion at a dosage very similar to theirs. Our results were in consistence with a recent 
paper (Frielingsdorf et al. 2004), which failed to replicate Zhao’s results. The number of 
BrdU labeled cells increased prominently throughout the brain, especially in SVZ, after 
BrdU continuous infusion for 28 days. But most of the cells could not be identified by 
any of the markers we used here. 
We used pre-embedding ICC to label the BrdU positive cells before cutting the 
brain tissue into ultra-thin sections. Since the BrdU ICC required DNA denaturation as a 
procedure to expose the nucleus, the morphology of many BrdU positive cells was not 
always pristine. In most of the cases, the cell membrane was damaged and few organelles 
were left outside the nucleus when observed under electron microscopy. This made it 
very difficult to identify the phenotype of these cells based solely on their components 
under electron microscopy. 
Even with the damaged cell membrane, one could tell that the cytoplasm was very 
limited in the BrdU labeled cells, occupying around 13% of the whole cell area on 
average. This may explain the difficulty of finding a phenotype-specific marker that 
could stain BrdU positive cells, especially those antibodies that recognize antigens within 
the cytoplasm.  
A high percentage of the BrdU positive cells we observed were located close to a 
mature neuron. These satellite cells might contribute to some of the “false positive” co-
 63 
localization of BrdU and neuronal markers observed with confocal microscopy by us and 
other researchers. 
One month after the start of osmotic minipump implantation, only uncommitted 
BrdU positive cells were observed. Whether these cells would continue to be 
uncommitted, or differentiate into a certain cell lineage is still not known. In our future 
studies, we would extend the time period after BrdU application to observe the 
differentiation of these cells. 
Several other important points are discussed below: 
 
Limitations of the confocal study 
Our results are in contradiction to several other papers showing evidence of 
constitutive neurogenesis in the striatum and the substantia nigra by confocal microscopic 
study. This technique, however, has its own limitations. It does not allow for the 
identification of cell membranes, and it is possible that some of these putative double-
labeled cells corresponded to small BrdU-positive cells closely associated to neighboring 
cells. By combining this technique with the electron microscopic study, we could have a 
more complete look at the identity of the stem/progenitor cells and their progeny. 
 
Astrocytes might serve as stem/progenitor cells in the CNS 
When observed under electron microscope, the BrdU labeled cells showed some 
characteristics of an astrocyte. They have light cytoplasm containing very few ribosomes 
and intermediate filament. It has long been speculated since the discovery of glia cells in 
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the CNS that neurons and glia cells originated from different progenitors. As described 
below, this may not be the case, and astrocytes may directly give rise to mature neurons. 
Our results were consistent with several studies (Doetsch et al. 1999 a, b; Laywell 
et al. 2000; Seri et al. 2001) showing that stem/progenitor cells may exhibit features of 
astrocytes and express GFAP, the marker widely accepted as the marker for mature 
astrocytes. By using transgenic mice expressing GFP under the promoter of nestin, 
Filippov et al. (2003) demonstrated astrocytic features in nestin-GFP-positive cells. One 
recent publication (Garcia et al. 2004) used two transgenic strategies to show that GFAP-
expressing cells residing in the SVZ and SGZ were predominantly responsible for the 
constitutive neurogenesis in mice. One separate report showed direct evidence that 
astrocytes may give rise to new neurons in the adult mammalian hippocampus (Seri et al. 
2001).  
Whether the BrdU+ cells we identified in the striatum, hippocampus, and 
substantia nigra would further differentiate into mature neurons was unknown at this 
point. To address this issue, we need to wait for a longer period after the BrdU 
administration with/without GDNF treatment to evaluate the ultrastructural 
characteristics or the BrdU labeled cells. 
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Figure 3.1 – Double-label immunoflourescence staining of BudU and TH in the 
substantia nigra of BrdU treated rats. There was extensive BrdU labeling (red) in the 
substantia nigra from BrdU infusion into the lateral ventricle, but none of the 
dopaminergic neurons (i.e. TH+ cells, in green) were co-labeled with BrdU (A-C). 
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N: Neuron; BV: Blood vessle 
 
 
 
 
 
Figure 3.2 – The morphology of BrdU labeled cells in the dentate gyrus. 
Immunostaining procedures for BrdU at the electron microscopic level revealed a 
number of small labeled cells in the hippocampus (A-C). Many of the BrdU labeled 
cells possessed a rounded nucleus: A. Here, a small cell with a BrdU positive nucleus 
(arrowheads) rests next to granule cells (N) in the dentate gyrus.  Scale bar = 500nm.  
B. This is an example of a solitary BrdU-labeled cell in the hippocampus surrounded 
by neurites.  Scale bar =1,000nm.  C. Other BrdU immunopositive cells were located 
next to blood vessels (BV), with features typical of astrocytes.  Scale bar =500nm. 
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Figure 3.3 – The morphology of BrdU labeled cells in the substantia nigra of animals 
that received continuous BrdU infusion for 28 days (A-C). A. BrdU labeling 
(arrowheads) in the nucleus of two adjacent cells indicates that they had recently 
divided.  Scale bar =1,000nm.  B. The typical BrdU-labeled nucleus (arrowheads) in 
the SN was small, round and intensely labeled.  This cell was located next to a neuron 
(N).  Scale bar =1,000nm.   C. A few labeled cells in the SN showed characteristics of 
oligodendroglia, with elongated, irregular nuclei containing clumped heterochromatin 
along the nuclear membrane. Scale bar =500nm. 
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Chapter Four 
 
The Effects of Intrastriatal Infusion of GDNF One Month after  
6-OHDA MFB Lesion on Stem Cell Proliferation and Differentiation  
in the Striatum, Hippocampus and Substantia Nigra 
 
 
Summary 
While there was no evidence for dopamine neurogenesis in normal young adult 
rats with GDNF treatment in our first set of experiment, we could not rule out the 
possibility that GDNF could promote neurogenesis in response to injury. The number of 
nigral TH+ neurons has been shown to increase with GDNF treatment in several 6-
OHDA lesion models (Bowenkamp et al., 1995, Kearns et al., 1997). It has also been 
reported that injury by itself could induce neurogenesis in neocortex and other brain 
areas. Therefore, this study was designed to explore the effects of GDNF on neurogenesis 
in combination with injury. A unilateral 6-OHDA lesion was introduced to produce 
degeneration of more than 95% of the dopaminergic neurons in the substantia nigra 
ipsilaterally. This would allow us to identify newly generated cells without interference 
of the injured cells undergoing DNA repair, which could also incorporate BrdU. One 
month after the 6-OHDA lesion, the same procedures as in the first study (as described in 
Chapter 2) were used in the delivery of GDNF vs. aCSF as vehicle, with the exception 
that TGFα was not used here. As in the previous study, altogether 600µg GDNF were 
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delivered into each trophic factor recipient during the 28-day period. BrdU was given 
through repeated i.p. injections at the same dosage as in the first study to allow 
quantitative comparison of BrdU labeling between the two studies. Apomorphine-
induced rotation tests were first used to screen the well lesioned animals before 
GDNF/aCSF treatment and to monitor functional recovery during the drug infusion 
(Table 4.1.). 
We found that GDNF failed to promote significant functional recovery during the 
period we tested (Fig. 4.1.). Similar to the first study, GDNF treatment significantly 
increased the number of BrdU labeled cells bilaterally in the dentate gyrus (Fig. 4.2.B) 
and ipsilaterally in the SNpc (Fig. 4.2.C). We still did not observe any newly generated 
dopaminergic neurons in the substantia nigra with traditional and fluorescence double-
labeling ICC techniques. 
 
Background 
 
Parkinson’s disease (PD) 
Affecting more than one million Americans alone, PD is a severe 
neurodegenerative disorder first formally defined by James Parkinson (1817). He noticed 
the shaking palsy (paralysis agitans) of the patients and described PD as the “saddest of 
diseases”. 
Clinical symptoms of the movement abnormalities include resting tremor, 
rigidity, bradykinesia (slowness of movement) and postural instability (Hoehn & Yahr, 
1998). PD is diagnosed pathologically by the loss of dopaminergic neurons, which are 
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pigmented, in the SNpc of the midbrain. This results in a depletion of dopamine content 
in nigral terminal areas in the basal ganglia, especially the putamen (Kish et al., 1988; 
Jellinger, 2001; Siderowf and Stern, 2003). Another important pathological feature is the 
presence of neurofilament inclusions (Lewy bodies) in all affected brainstem regions 
(Lang and Lozano, 1998a; Rascol et al., 2003).  
The etiology of PD remains poorly understood. To date, several genes have been 
found to be related to familial Parkinson’s disease including α-synuclein, parkin and 
ubiquitin carboxy-terminal-hydrolase-L1. However, since only about 5% of PD is 
inherited, environmental and other factors, such as oxidative stress, mitochondrial 
dysfunction and lack of neurotrophic support, may play important roles in neuronal 
degeneration associated with PD (Lindsay et al., 1993; Blum et al., 2001; Steece-Collier 
et al., 2002; Siderowf and Stern, 2003). 
The standard treatment for the disorder is to use a dopamine precursor or 
dopamine agonists to improve the motor symptoms. So far, L-dopa still remains the most 
effective drug during the early stages of the disease. However, L-dopa and other 
dopaminergic medications cannot halt disease progression, and prolonged use of these 
drugs not only produces unwanted side effects such as daily “on-off” motor fluctuations 
and dyskinesias (troublesome involuntary movements), but also results in the 
development of drug resistance in PD patients. Other therapeutic strategies have been 
developed to complement L-dopa therapy shortcomings. Among them are monoamine 
oxidase (MAO) B inhibitors, catechol- O-methyltransferase (COMT) inhibitors, 
anticholinergics and amantadine. Finally, surgical procedures, such as pallidotomy and 
particularly deep brain stimulation of the globus pallidus pars interna or subthalamic 
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nucleus are used for advanced PD patients with severe disability (Krack et al., 1999). 
Although, to a certain degree, these treatments help to relieve some of the symptoms, 
none of them has been found entirely safe or efficacious (Lindsay et al., 1993; Leonardi 
and Mytilineou, 1998; Rascol et al., 2003). Taken together, neither pharmacological 
treatments nor surgical interventions can stop or reverse the degenerative process in the 
nigrostriatal system. 
Although PD is still incurable, progress has been made to treat it with cell 
replacement therapies (Dunnett et al. 2001).  Adrenal chromaffin cells (Olson & 
Malmfors, 1970), fetal dopamine cells, embryonic stem cells, and special gene-
transduced cells (Nakao et al. 2000) have all been used to test for transplantation into 
certain brain areas, with different extent of success. Despite this, there are a lot of ethical 
debates and political restrictions imposed upon these procedures, especially in the case of 
manipulating embryonic stem cells. 
Pathological findings from PD patients have shown that around 50%-70% of 
dopaminergic neurons in the substantia nigra and about 80% of the dopamine content in 
the putamen are lost by the onset of clinical symptoms (Lindsay et al., 1993; Lang and 
Lozano, 1998a; Blum et al., 2001). This suggests that the nigrostriatal system has 
considerable plasticity to compensate for the loss of dopaminergic neurons. Moreover, 
the spared dopamine cells in the substantial nigra may provide an opportunity for 
neuroprotective and neurorestorative treatment. The time window between the early stage 
PD patient (with 50-60% dopamine neurons left) and the advanced PD patient (with only 
20-40% dopamine neurons left) can be several years (Bernheimer et al., 1973; Hely et al., 
1999). Any treatment that can slow down or stop the dopaminergic cell death during this 
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period will be very beneficial for PD patients in terms of improving symptoms, changing 
the quality of life and lengthening patients’ life expectancy. One promising therapeutic 
approach is the use of neurotrophic factors to promote the survival and growth of 
dopaminergic neurons. The ultimate goal is to slow or halt neuronal degeneration at an 
early stage and to stimulate compensation and growth in these cells (Moller et al., 1996; 
Collier and Sortwell, 1999). 
 
GDNF as a promising drug in the treatment of PD 
GDNF is the most potent trophic factor for the dopaminergic neurons; it exerts its 
function by increasing the cell number, cell size, axon sprouting and transmitter uptake 
(Hudson et al. 1995). The in vivo studies also revealed its potent protective effects under 
several different injury conditions such as axotomy (Beck et al., 1995) or 6-OHDA 
lesions in rats (Boewenkamp et al., 1995; Kearns and Gash, 1995; Sauer et al., 1995), and 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesions in mice (Tomac et al., 
1995) and rhesus monkeys (Gash et al., 1996). Both 6-OHDA and MPTP lesions have 
been widely accepted and are used to produce animal models with Parkinsonian features. 
According to earlier work in our lab (Kearns et al. 1997), administration of GDNF before 
6-OHDA lesions can effectively protect and restore TH-immunoresponsive dopaminergic 
neurons by increasing the number of dopaminergic neurons and the tissue level of 
dopamine. Similar results were observed in MPTP lesioned rhesus monkeys that received 
continuous infusion of GDNF into the lateral ventricle or the striatum (Grondin et al. 
2002). 
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Because GDNF and neurturin could rescue dopamine neurons in animal models 
of Parkinson’s disease, hopes have been raised that GDNF family ligands may be new 
drugs for the treatment of neurodegenerative diseases. Recent clinical trial on PD patients 
(Gill et al. 2003; Slevin et al. 2004) hold renewed hope for the treatment of this 
devastating disease. 
 
MFB lesion with 6-OHDA 
The structure of 6-OHDA is very similar to that of dopamine. It is a selective 
neurotoxin (Ungerstedt, 1968; Breese and Traylor, 1970; Uretsky and Iversen, 1970) that 
can be directly transported into dopaminergic and noradrenergic neurons via high-affinity 
catecholamine uptake systems. This results in the intraneuronal accumulation of 
cytotoxic compound, such as H2O2 and 6-OHDA quinone. Subsequently, these lead to the 
degeneration of the terminal axons. When the loss of terminals for a given cell exceeds a 
certain threshold, the cell bodies may degenerate as well and eventually die (Cohen & 
Werner, 1994). 
Since 6-OHDA cannot pass the blood-brain barrier, it is necessary to administer it 
directly by stereotaxic injection to target a specific part of the nigrostriatal dopaminergic 
pathway and produce an animal model of PD. The striatum, the substantia nigra and the 
MFB are three locations widely used as the target of 6-OHDA delivery. 
The MFB consists of the ascending dopaminergic axons collected from both the 
ventral tegmental area (VTA) and the substantia nigra. It passes to the ventromedial edge 
of the internal capsule and enterd the caudate-putamen by several routes. 
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When injected into the substantia nigra or MFB, dopaminergic neurons start 
degeneration within 24 hours and die with no evidence of apoptosis (Jeon et al. 1995). 
Injection of 6-OHDA into the MFB not only kills dopaminergic neurons in the 
substantia nigra and causes extensive loss of cells in the VTA, but also induces 
degenerative changes of dopamine terminals in the striatum. The 6-OHDA MFB lesion 
could serve as a good animal model because clinical dysfunctions required very large 
brain lesions. In the human, mild neurological impairments were correlated with 
dopamine depletions of 80% in the caudate nucleus and 90% in the putamen, whereas 
severe deficits were associated with near total dopamine depletions. It has been estimated 
that the MFB lesion in rats could cause the degeneration of more than 95% of the 
dopaminergic neurons in the substantia nigra. Extracellular dopamine concentrations can 
be maintained at adequate levels even after extensive destruction of dopaminergic 
neurons. However, this compensation would be inadequate to maintain dopaminergic 
control over striatal cell function after very large lesions, such as 6-OHDA MFB lesion, 
and eventually would lead to neurological deficits. 
 
Apomorphine-induced rotation test 
An apomorphine-induced rotational test was used to assess the extent of neuronal 
loss and ipsilateral dopamine depletion in the striatum following lesions of the substantia 
nigra (Mendez and Finn, 1975).  
Apomorphine binds to the D2 receptor as a postsynaptic agonist. Injection of 
apomorphine induces animals to turn in circles vigorously in the direction away from the 
lesioned side. With a 6-OHDA MFB lesion, more than 95% of dopaminergic neurons had 
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degenerated. This resulted in an upregulation of D2 receptors on ipsilateral striatum, a 
phenomenon called denervation supersensitivity. It has been proposed that the receptor 
denervation supersensitivity is the cause of this behavior. Since we could not get rotation 
with the limited cell loss seen in 6-OHDA partial lesions, the rotation test could be used 
to monitor the effectiveness of a 6-OHDA lesion and to identify animals with complete 
unilateral 6-OHDA lesions (Carman et al., 1991). 
In this set of experiments, rats demonstrating a minimum of 300 contralateral 
turns on average in 50 minutes were considered to be well lesioned. Only complete 
circling was counted over this time period. 
 
Effects of GDNF on damaged dopaminergic neurons 
GDNF has been shown to have potent effects on dopaminergic neurons in 
response to injury. It could protect against loss of dopaminergic neurons and reduction of 
striatal dopamine content when administered to rats prior to or shortly after 6-OHDA 
lesions (Kearns & Gash, 1995; Sauer et al. 1995; Choi-Lundberg et al. 1997; Cass & 
Manning, 1999). It has also been reported that GDNF protects against dopaminergic 
neuronal loss and dopamine depletion caused by MPTP and methamphetamine (Tomac et 
al. 1995; Cass, 1996). When administered after either 6-OHDA lesions or MPTP lesions, 
GDNF could lead to partial histochemical, neurochemical and functional recovery in 
rodents and in non-human primates (Hoffer et al. 1994; Bowenkamp et al. 1995; Gash et 
al. 1996; Lapchak et al. 1997; Cohen et al. 2003).  
It has been hypothesized that GDNF specifically affects dopamine neurons in at 
least three ways.   
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(1)  Pharmacological effects: it upregulates dopamine neuron activities;  
(2) Neuroprotective effects: dopamine neurons exposed to GDNF are partially 
protected from some neurotoxins like 6-OHDA;  
(3) Neurorestorative effects: GDNF also promotes the growth and regeneration of 
dopamine neurons that have been injured, for example, from neurotoxins like 6-OHDA.   
There is some evidence that neurogenesis could be a fourth action of GDNF. It 
refers to an ability of GDNF in promoting the development of new neurons to replace 
dopamine neurons lost to degenerative processes, such as in PD.  
While there was no evidence for dopamine neurogenesis in normal young adult 
rats in our first experiment, the number of nigral TH+ neurons has been shown to 
increase with GDNF treatment in several 6-OHDA lesion models (Bowenkamp et al., 
1995, Kearns et al., 1997). While the interpretation of these data has been that the 
additional TH+ cells represented restored neurons, an alternative interpretation is that 
they are new neurons. 
The neurogenesis of new dopamine neurons, if substantiated, has profound 
implications for treating Parkinson’s disease.  It offers the possibility of halting or 
possibly even reversing the disease process.   
 
Cell genesis in response to injury 
The damage of the adult CNS not only breaks the normal communication between 
healthy neurons, but also initiates a cascade of events leading to neuronal degeneration 
and death. This includes demyelination of axons, axonal retraction, aberrant axonal 
sprouting and cell death (Horner & Gage, 2000). In contrast to fish and amphibians, the 
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adult rodent and mammalian CNS lacks the ability to regenerate new neurons and regrow 
functional axons after injury. This is not entirely due to the lack of regenerative abilities 
of the CNS neurons, but also because of the damaged environment that either prevented 
or failed to support regeneration. In fact, it has been demonstrated for decades that CNS 
neurons do have regenerative capabilities (Richardson et al. 1980) when placed into the 
proper environment. Cell survival, axonal growth, re-myelination and synapse formation 
are four steps required by the regeneration of the CNS. 
Transplanting cells from stem cell lines into the damaged brain area has been 
investigated by a number of groups to determine possible therapeutic applications for 
neurotraumatic and neurodegenerative diseases. But this approach has its limitations. 
First of all, there is potential immunological incompatibility between the transplanted 
stem cells and the host brain. Second, stem cells come from existing cell lines, which 
may have been maintained in vitro for many generations. Chromosomal and genetic 
abnormalities increase with each generation of cells in culture. Finally, there are ethical 
issues regarding the use of embryonic stem cells in research; and the sources of stem cells 
are limited. Thus, an alternate approach, with possibly fewer limitations, would be to 
activate endogenous adult stem cells and to stimulate their proliferation and 
differentiation into appropriately functioning neurons. 
It has been recently demonstrated that neural stem/progenitor cells migrate to sites 
of pathological insult such as various types of brain injury and tumors (Arvidsson et al., 
2002; Parent et al., 2002; Iwai et al., 2003; Fricker et al., 1999; Aboody et al., 2000; Li et 
al., 2002). Other studies have shown that injury of the adult brain could promote 
proliferation of stem/progenitor cells (Parent et al. 1997; 1999; Bengzon et al. 1997; Liu 
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et al. 1998; Gould & Tanapat, 1997) and reactivate their migration and differentiation 
(Wang et al., 1998; Leavitt et al., 1999). Limited neurogenesis was also detected after 
specific lesions in the adult neocortex (Magavi et al., 2000). In some cases, neurogenesis 
may even support the recovery of function (Nakatomi et al. 2002). 
 
Materials and Methods 
 
MFB lesion 
The 6-OHDA MFB lesion model used in this study was generated as described 
previously (Boewencamp et al. 1995). In the lesion-infusion study, animals were 
anesthetized with chloral hydrate (Sigma, St. Louis, MO; 300mg/kg, i.p.) and received a 
stereotaxic injection of 6-OHDA into the right MFB (coordinates- AP: -4.4mm, ML: -
1.3mm, DV: -8.0mm) using Bregma as a reference. The 6-OHDA solution (9µg/4µl 
saline containing 0.02% ascorbic acid) was freshly made and injected using a 10µl 
syringe (Hamilton Company, Reno, NV) at a rate of 0.5µl per minute. The needle was 
kept in place for an additional five minutes before retraction. 
 
Apomorphine-induced rotation tests 
Starting at one week after the MFB lesion, all rats received apomorphine induced 
rotation tests once a week. The animal received a single subcutaneous injection of 
apomorphine (0.05mg/kg in saline containing 0.02% ascorbic acid) and was contained in 
a square box. Their circling behaviors were caught in tapes and only complete circling 
was counted over 50 minutes. Rats demonstrating a minimum of 300 contralateral turns 
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on average were considered to be well lesioned and were used for the subsequent infusion 
experiments. Earlier reports of Hudson et al. (1993) have shown that more than 99% of 
striatal dopamine content is depleted with similar criteria. The behavioral tests continued 
for once a week during the drug continuous infusion. 
 
Drug continuous infusion 
One month after the 6-OHDA lesion, all rats with good lesions as screened by the 
apomorphine-induced rotation tests were randomly divided into two groups (n=9). One 
group received GDNF and another received aCSF. Animals were anesthetized with 
chloral hydrate (300mg/kg, i.p.) and placed in the stereotaxic device. A small hole was 
drilled in the skull over the right frontal cortex and the 5 mm cannula, which was 
attached to the Alzet osmotic minipump (Durect corporation, Cupertino, CA; model 
2002: 200µl/14days), was stereotaxically implanted into the right caudate-putamen 
(coordinates- AP: 1.2mm, ML: -2.7mm) using Bregma as a reference. The pump was 
implanted subcutaneously and the infusate (200µl GDNF or aCSF) was delivered directly 
into the striatum at a rate of 0.5µl/hour. The concentration of GDNF was  
100µg/200 µl. At the 14th day of infusion, the animal was anesthetized and placed back 
in the stereotaxic device. A small incision was made on the back skin and the pump was 
replaced by a new one full of the same infusate (200µl). 
 
BrdU injection 
The procedures were the same as described in the first study (Chapter 2). 
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Tissue collection 
At the end (i.e. the 28th day) of drug infusion, the animal was anesthetized with 
ketamine and sacrificed by transcardial perfusion of 4% paraformaldehyde. The brain 
was collected and postfixed overnight, and then it was immersed in 30% sucrose for three 
days before slicing on a freezing microtome. Samples were sectioned at the thickness of 
30µm and stored in the cryoprotectant at -20°C. 
 
Immunocytochemistry 
The same procedures and similar markers were used in this study as the previous 
studies. 
 
Bioquant 
The Bioquant Image Analysis System was used to quantify the newly generated 
cells in certain brain areas. The areas being investigated included the caudate-putamen 
and the substantia nigra. The sections used for counting cells in the striatum were labeled 
with BrdU and counter-stained with neutral red. And the sections used for counting cells 
in the substantia nigra were double labeled with BrdU and TH. The area (number of 
pixels) of the regions was quantified. The number of BrdU-positive cells in each region 
was estimated. On each section, a 300µm×300µm grid was superimposed with a 
300µm×300µm counting chamber placed on each intersection. All cells completely 
within the boundaries of the chamber or crossing the upper or right side of the chamber 
were counted. 
 
 81 
Statistical analysis 
The results are expressed as means ± SEM. Statistical significance in each side 
between the treatment groups was assessed using two-way analysis of variance 
(ANOVA) with side as within-subjects repeated factor and treatment as the between-
subjects factor. Subsequantly, the effect of GDNF treatment was assessed for each side 
separately by two-tailed Student’s t-tests for independent samples. Unequal variance was 
assumed. The procedures used to compare the BrdU immunoreactivity in the dentate 
gyrus of the two treatment groups were the same as described in Chapter 2. For 
apomorphine-induced rotation tests, only full circles each animal turned away from the 
lesion side in 50 minutes were counted. The number was averaged within each treatment 
group and presented. 
 
Immunofluorescent staining  
Free-floating sections stored in cryoprotectant were used. For fluorescent double-
labeling, they were first pre-treated, blocked by 4% normal goat serum, and incubated in 
anti-BrdU primary antibody (as described above) for 48 hours, and rinsed thoroughly and 
incubated with Alexa Fluor 568 goat anti-rat antibody (1:500, Molecular Probes, Eugene, 
OR) for one hour. After being rinsed in PBS, the sections were blocked by 4% normal 
goat serum again before being incubated in another primary antibody (as listed above) for 
one to two days. Corresponding to the source of the primary antibody applied, Alexa 
Fluor 488 secondary antibody was used following complete rinsing in PBS. Fluorescent 
sections were evaluated using Leica TCS laser scanning confocal microscope systems 
(Am Friedensplatz, Mannheim, Germany). 
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Results 
 
BrdU labeling in the striatum, hippocampus and substantia nigra  
The number of BrdU labeled cells were quantified by Bioquant software system 
two months after the 6-OHDA lesion and one month after the start of drug continuous 
striatal infusion. 
In both the dentate gyrus and the substantia nigra, the drug recipients with lesion 
showed a significantly lower number of stem/progenitor cells than their normal 
counterpart as described in our first study in Chapter 2 (Fig. 2.5.B.-C.). In the dentate 
gyrus of lesioned animals, the number of BrdU positive cells in each 100µm-long 
segment was only about one half of the number in normal animals with the same 
treatment. 
Comparing to vehicle treatment, GDNF did not show significant effects on 
stem/progenitor cell proliferation in either side of the striatum (Fig. 4.2.A.). GDNF 
significantly increased the number of BrdU+ cells in the dentate gyrus bilaterally (Fig. 
4.2.B) and in the ipsilateral substantia nigra (Fig. 4.2.C). The number of BrdU positive 
cells in each 100µm-long segment of dentate gyrus in GDNF recipients was increased by 
~45%, compared to vehicle controls.  The increase was greater in the ipsilateral 
substantia nigra, where the number of BrdU+ cells was ~167% larger in the substantia 
nigra of the GDNF recipients. 
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No significant functional recovery was observed under continuous GDNF treatment in 
the striatum 
As shown in Fig 4.1, although there appeared to be a slight improvement during 
the first week of infusion in animals treated with GDNF, the recovery did not last for 
long, and the difference between the two treatment groups diminished after three weeks 
of drug infusion. 
Because of the high variation in each group, overall the recipients of GDNF 
infusion into the striatum did not show significant functional recovery compared to 
vehicle recipients at any time point. 
 
No neurogenesis in the substantia nigra was observed under GDNF treatment  
We used both the light microscopic double-labeling and confocal 
immunofluorescent double-labeling techniques to evaluate the existence of neurogenesis. 
With the exception of BrdU+/Nestin+ cells in the SVZ and BrdU+/NeuN+ cells in the 
denate gyrus, no double-labeled cells were found in our survey in any of the treatment 
groups. An additional search for BrdU+/TH+ cells was conducted using light 
microscopic double-labeling when counting every BrdU+ cell in every 6th section 
through the rostral caudal extent of the substantia nigra.  While 779 BrdU+ cells were 
counted in the 18 rats (controls and GDNF-treated) used in this study, none were TH+ 
(Table 4.2.). 
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Discussion 
One month after the injury, the number of stem/progenitor cells in the striatum, 
the dentate gyrus of the hippocampus, and the substantia nigra were evaluated with cell 
counting of BrdU+ cells. When comparing to our first study with drug treatment to 
normal rat brain, we found fewer BrdU labeled cells in the dentate gyrus and the 
substantia nigra in drug recipients with 6-OHDA lesions. This result is in accordance 
with the findings of Hoglinger et al (2004) who showed that there were fewer precursor 
cells in the SVZ and dentate gyrus in mice treated with MPTP and in PD patients as 
compared to the control group. This may be due to the loss of dopaminergic control over 
the SVZ and the SGZ.  
GDNF continuous infusion increased the proliferation of stem/progenitor cells in 
the dentate gyrus and the substantia nigra comparing with aCSF treatment.  
Neurogenesis in the dentate gyrus was confirmed by confocal microscopy with 
BrdU and NeuN. With GDNF treatment, there was a significant increase of BrdU 
positive cells in both sides of the dentate gyrus with or without injury, suggesting that 
GDNF might increase neurogenesis in the hippocampus and play an important role in 
learning and memory. As mentioned before, it would be very important to test whether 
this kind of stem cell proliferation and differentiation could be linked to the improvement 
in behavioral tests on cognition. 
GDNF did not render further differentiation of stem/progenitor cells into 
functional neurons in the substantia nigra, though there was a significantly higher number 
of BrdU+ cells in the ipsilateral side under GDNF treatment.  
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GDNF did not provide functional recovery to rats one month after the 6-OHDA 
lesion.  
Since the ipsilateral substantia nigra was severely impaired and neuronal 
projections into the striatum had been lost by one month after 6-OHDA injection into the 
MFB, we decided to test another experimental approach, one in which we delivered 
GDNF directly into the substantia nigra before a 6-OHDA lesion (Chapter 5). The same 
procedure has been reported (Kearns et al. 1997) to show potent protective effects of 
GDNF on dopaminergic neurons as measured by improved behavior, neurochemistry and 
quantitative morphology. 
 
The MFB lesion model 
The complete unilateral 6-OHDA-lesion model has its own drawbacks (Lee et al., 
1996). First it is the “sudden and massive toxic insult,” resulting in an instant loss of 
dopamine neurons rather than a gradually progressive neuronal loss. Second, there is a 
difficulty in administering the proper dosage when a submaximal lesion is desired. 
However, because our interest here is the function of the newly differentiated 
dopaminergic neurons in the striatum, it is necessary to eliminate endogenous 
dopaminergic neurons. The apomorphine-induced behavioral test was used on the 
animals after the 6-OHDA injections to screen for fully developed lesions. Only those 
animals that have complete lesions were used for further study. 
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The lack of functional recovery with GDNF treatment one month after MFB lesion 
As seen in Fig. 4.1., the apomorphine-induced rotation test did not show 
functional recovery of the lesioned animals with GDNF treatment when compared with 
the aCSF recipients. 
This is the first study by our group in a decade in which intracerebral GDNF 
treatment has failed to promote behavioral improvements in animals with nigral 
dopaminergic lesions (Gash et al. 1996 and Grondin et al. 2002).   
In this study, we gave a nearly complete lesion of dopaminergic neurons through 
the MFB, and waited for a month before starting the continuous GDNF infusion. In 
contrast to similar studies by others (Bowenkamp et al., 1995: Winkler et al., 1996), there 
was less than 1% of the normal complement of nigral TH+ neurons remaining in the 
lesioned (data not shown), GDNF treated substantia nigra and MFB was disrupted. Thus, 
it was hard for GDNF to be retrogradely transported back to the substantia nigra and 
exert its function.  
It is still possible that a population of cells may be responding to the GDNF, but a 
proper location and timing for GDNF treatment is essential for its function. 
 
Effects of GDNF on stem/progenitor cell proliferation 
GDNF treatment significantly increased the number of stem/progenitor cells 
labeled with BrdU bilaterally in the dentate gyrus of the hippocampus. Since there has 
been evidence of dopaminergic control over SGZ precursor cell proliferation (Hoglinger 
et al. 2004), GDNF might be able to exert its function on dopaminergic fibers that form 
functional connections with the precursor cells. 
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Besides the hippocampus, there was also a significantly higher number of BrdU+ 
cells in the ipsilateral substantia nigra in GDNF recipients than in animals receiving 
aCSF. 
 
The lack of neurogenesis in the substantia nigra with GDNF treatment in response to 
injury 
Since the previous study of BrdU continuous infusion has shown that our 
procedure is effective in labeling newly generated dopaminergic neurons in the basal 
ganglia, there remains to be two possibilities in explaining the absence of any 
BrdU+/TH+ cells in our studies: 
 (a)  that new dopamine neurons are not generated under the conditions of our 
studies. 
 (b)  that our procedures are killing newly generated dopamine neurons. 
 The apomorphine-induced rotation data (Figure 4.1.) provided some support that 
BrdU incorporation may be too detrimental to newly generated dopamine neurons.  
 Thus, we felt that another set of experiments using milder lesions was needed to 
determine if dopamine neurogenesis does significantly contribute to GDNF-induced 
structural and functional recovery of the nigrostriatal dopaminergic system. 
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Table 4.1 – Procedures undertaken for GDNF/vehicle treatment. Each animal received a 
unilateral 6-OHDA MFB lesion, and was screened for good lesion before pump 
implantation. Animals were randomly assigned into two groups, nine animals in each 
group that received either GDNF or aCSF as vehicle.  Behavioral tests were used to test 
their motor function during the 28 days of drug infusion. 
Day 30-57 
Group 
No. Day 1 Day 21, 28 Day  
30-34 
Day  
30-57 
Day 36, 
43, 50 Day 58 
1 GDNF (n=9) 
2 
6-OHDA 
Complete 
Lesion 
Rotation 
Testings 
BrdU i.p. 
injections 
aCSF 
(n=9) 
Rotation 
Testings Perfusion 
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Table 4.2 - BrdU+ cell counts in the substantia nigra. Every 6th section through the 
midbrain in each animal was used for cell counting. The total number of BrdU+ cells on 
each side of each treatment group was summed in this table. Although altogether  
779 cells were observed with BrdU immunoreactivity, no BrdU+/TH+ double labeled 
cell was observed in each area. 
 
 
 
 
 
 Right Side Left Side 
Vehicle GDNF Vehicle GDNF 
0 0 0 0 
Substantia Nigra 
BrdU+/TH+ neurons 
BrdU+/TH- cells 96 257 158 268 
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Figure 4.1 – Rotation behavior tests induced by apomorphine 
administration after either vehicle or GDNF treatment. The graph 
suggests a slight improvement during the first week of infusion in 
GDNF recipients, but overall, there is no significant difference between 
two groups. 
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Figure 4.2A – Bioquant cell counting of BrdU labeled cells in the striatum. BrdU 
labeled cells from 1 in every 6th whole brain sections in the striatum of each 
animal were screened and counted. There was no significant difference in BrdU 
labeling on both sides between the two treatment groups. 
Right side: F=0.721, P=0.411; Left side: F=2.646, P=0.128. 
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Figure 4.2B – Bioquant cell counting of BrdU labeled cells in the dentate gyrus. BrdU 
labeled cells from 1 in every 6th whole brain sections in the dentate gyrus of each 
animal were screened and counted. The length of each corresponding dentate gyrus 
was also measured. The average number of BrdU-positive cells in each 100µm-long 
segment of the dentate gyrus was calculated for each section and averaged in each side 
of the drug treatment groups, as shown above. There was significantly higher number 
of BrdU labeled cells in both sides of the dentate gyrus with GDNF treatment than 
with vehicle treatment.  (*: P<0.05) 
Right side: F=8.387, P=0.011; Left side: F=7.998, P=0.013. 
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Figure 4.2.C – Bioquant cell counting of BrdU labeled cells in the substantia 
nigra. Number of BrdU labeled cells in the SN of GDNF-treated animals was 
significantly higher in the ipsilateral hemisphere than that in the vehicle 
recipients. (*: P<0.05) 
Right side: F=13.873, P=0.002; Left side: F=1.703, P=0.213. 
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Chapter Five 
 
The Effects of a Single Intranigral Injection of GDNF Six Hours before 
 6-OHDA Partial Lesion on Stem Cell Proliferation and Differentiation  
in the Striatum and Substantia Nigra 
 
Summary 
In this study, we followed the procedures reported by Kearns et al. (1997) to 
deliver GDNF six hours before a 6-OHDA intranigral (partial) lesion. Consistent with 
their report, we found improvement of dopamine, 3,4-dihydroxy phenylacetic acid 
(DOPAC) and homovanillic acid (HVA) tissue levels in both the substantia nigra and the 
striatum (Fig. 5.1.A-F). Despite this, we still did not observe any newly generated 
dopaminergic neurons in the substantia nigra. Thus, we conclude that under the 
experimental protocols we employed, GDNF could not induce neurogenesis in the 
substantia nigra with or without injury. 
 
Background 
 
The 6-OHDA partial Lesion 
As mentioned above, parkinsonian symptoms could be induced by giving animals 
a neurotoxin 6-OHDA. The toxin results in brain pathology that mimics what is seen in 
human PD patients. A single stereotaxic injection of 6-OHDA in the SNpc leads to 
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degeneration of less than 70% dopaminergic neurons, less severe than the MFB lesion. 
Thus, this produces an animal model with a partial lesion. 
 
GDNF protective effects on dopaminergic neurons 
Kearns et al. (1997) found that intranigral injection of GDNF provided protection 
against a 6-OHDA partial lesion. Young adult male adult Fisher 344 rats were used in the 
study. GDNF (10µg/2µl) was injected into the SNpc six hours before an injection of 6-
OHDA (8µg/2µl) in the same site. ICC staining for TH and HPLC for dopamine and 
DOPAC were used to observe the morphological and neurochemical effects of GDNF. 
The results showed that GDNF significantly increased the survival of dopaminergic 
neurons in the substantia nigra, and the GDNF recipients displayed significantly higher 
level of dopamine and DOPAC in both the striatum and the substantia nigra three weeks 
after the lesion than lesioned controls. Interestingly, in the substantia nigra of GDNF pre-
treated animals, the number of TH-immunoreactive cells in the lesioned side was 
consistently higher than the number in the nonlesioned contralateral side. The HPLC 
results revealed dopamine levels in the substantia nigra of GDNF pre-treated animals that 
tended to be higher on the lesioned side than on the contralateral side (the difference was 
not statistically significant).  
 
High performance liquid chromatography (HPLC) on dopaminergic system 
The restoration of the striatal dopamine level might be critical to ensure the 
recovery of dopaminergic function. Dopamine may be inactivated by MAO to release 
CO2 and form DOPAC. DOPAC may be further metabolized by COMT into HVA. 
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Alternatively, if dopamine is acted upon first by COMT, it is transformed into 3-
methoxytyramine (3-MT), which may become HVA in the presence of MAO. Both 
pathways end at HVA, but each has a different intermediate product. 
In the long term, dopamine is eventually inactivated by the degradative enzymes 
MAO and COMT. MAO is predominantly intracellular and COMT extraneuronal. 
Therefore, tissue levels of DOPAC and HVA will provide an indication of the 
intracellular and extraneuronal dopamine tissue levels, respectively. 
 
Materials and Methods 
 
Animals and anesthetization 
Animals used here have the same characteristics as described in the first study. 
Nine animals were used in each treatment group. 
 
GDNF and 6-OHDA injections 
The animals were randomely divided for two groups. One group received GDNF, 
and the other group received citrate as vehicle solution. Six hours after the drug pre-
treatment, all the animals received a single intranigral 6-OHDA injection. 
All surgeries were performed using sterile instruments and aseptic conditions such 
as disinfections with isopropyl alcohol. The scalp of the anesthetized animal was shaved 
and the animal placed in the stereotaxic device. The skull was exposed with a small 
incision and a small hole was drilled in the skull over the posterior cortex for stereotaxic 
injection of drugs. Either GDNF or citrate was delivered directly over the right SNpc 
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using the coordinates (AP: -5.4 mm; ML: -2.2 mm; DL: -8.5 mm from skull) through a 
Hamilton syringe (26 gauge blunt tapered needle). Bregma line was used as a reference 
for stereotaxic injection. Altogether 2µl 10mM Citrate/120mM NaCl buffer (pH 5.5) or  
2 µl GDNF was delivered at a rate of 0.2 µl/minute. The concentration of GDNF solution 
was 5µg/µl. The needle was left in place for an additional five minutes following the 
injection and then slowly withdrawn. The incision was closed with wound clips. The 
animal was kept warm on a heating pad until awaking, and then placed back into the cage 
with food and water. The animal was closely monitored for signs of distress from surgery 
and anesthesia.  
After six hours, the animal was re-anesthetized by chloral hydrate and the incision 
was opened. A total of 8µg/2µl 6-OHDA was injected by a Hamilton syringe through the 
same hole mentioned above with the same stereotaxic coordination. Other procedures of 
injection were the same as described above. After injection, the incision was closed with 
wound clips. The rat was returned to the cage after awaking and checked daily within the 
first week after surgery. 
 
BrdU injection 
The procedures were the same as described in the first study (Chapter 2). 
 
Tissue collection for ICC 
One month after the drug treatment and 6-OHDA partial lesion, the animals were 
anesthetized with Ketamine and sacrificed by transcardial perfusion of 4% 
paraformaldehyde. The brain was collected and postfixed overnight, and then it was 
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immersed in 30% sucrose for three days before slicing on a freezing microtome. Samples 
were sectioned at the thickness of 30µm and stored in the cryoprotectant at -20°C. 
 
ICC and immunofluorescent study 
The same procedures and similar markers were used here as in the previous 
studies. The confocal microscope procedures were used to identify BrdU+/TH+ double 
labeled cells on one twenty-fourth of total brain sections in each animal of both treatment 
groups. 
 
Tissue collection for HPLC 
Animals used for HPLC study were sacrificed by decapitation while under CO2 
anesthesia and the brains were quickly removed. By using an ice-chilled brain mold 
(Rodent Brain Matrix, ASI Instruments, Warren, MI), a 2-mm coronal slab of brain was 
cut; the striatum was dissected from each half of the slab separately. Similarly, the 
substantia nigra was dissected from each side of a 2 mm-thick coronal slab through the 
midbrain, respectively. The tissue samples were placed in preweighed vials, weighed, and 
frozen on dry ice. Samples were stored at −70 °C until assayed for dopamine and its 
metabolites by HPLC (Hall et al. 1989) using electrochemical detection.  
 
HPLC 
Tissue levels of dopamine and DOPAC from each side of the striatum and 
substantia nigra were determined by HPLC analysis with electrochemical detection (Hall 
et al. 1989). Peaks were identified by retention times of standards. Peak heights were 
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used to quantify the recovery of internal standards and the amounts of monoamines and 
metabolites. Results were expressed as ng/g wet weight of tissue. 
 
Statistical analysis 
The results are expressed as means ± SEM. Levels of dopamine and DOPAC 
were expressed as nanograms per gram of wet weight of tissue and averaged within each 
treatment groups as presented. Statistical significance in each side between the treatment 
groups was assessed using two-way analysis of variance (ANOVA) with side as within-
subjects repeated factor and treatment as the between-subjects factor. Subsequantly, the 
effect of GDNF treatment was assessed for each side separately by one-tailed Student’s t-
tests for independent samples. Unequal variance was assumed. 
 
Results 
 
HPLC study confirmed protective effects of GDNF on dopaminergic neurons 
In GDNF recipients, dopamine levels in ipsilateral substantia nigra of the lesioned 
animals were significantly higher than that in the citrate recipients (Fig 5.1.A). 
Levels of the dopamine metabolites were also measured. The tissue levels of 
DOPAC (Fig. 5.1.C) and HVA (Fig 5.1.E) in the ipsilateral striatum was significantly 
higher in the GDNF treated group than that in the citrate treated group. 
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No neurogenesis in the substantia nigra was observed under GDNF treatment  
No BrdU+/TH+ or BrdU+/DAT+ cells were observed in the substantia nigra with 
the double-labeling immunofluorescence study. 
 
Discussion 
GDNF is a potent trophic factor on dopaminergic neurons with protective and 
restorative effects. It has been reported repeatedly that the number and size of 
dopaminergic neurons increased in the substantia nigra under GDNF treatment in 
response to injury (Beck et al. 1995; Tomac et al. 1995; Gash et al. 1996). Specifically in 
rats with 6-OHDA lesions, GDNF has been reported to have strong neuroprotective and 
neurorestorative effects on the dopaminergic system (Boewenkamp et al. 1995; Kearns 
and Gash, 1995; Sauer et al. 1995). This study followed almost exactly the procedures 
used previously by Kearns et al (1997) in their neuroprotective study. In their report, 
there were significant increases of the dopamine and DOPAC tissue levels in 6-OHDA 
lesioned animals with GDNF treatment.  Thus, we used the one-tailed t-test in comparing 
the dopamine and DOPAC tissue level in the striatum and the substantia nigra in this 
study. Our HPLC results were comparable to the neurochemistry results reported in that 
publication. The dopaminergic neurons were completely protected by GDNF according 
to the paper. Based on our observation, the GDNF recipients in our experiments seem to 
have more TH+ cells in the substantia nigra compared to the vehicle treated group. Since 
the paper by Kearns et al. (1997) reported significantly increased number of TH+ cells 
with GDNF treatment and our focus was on the existence of neurogenesis, we did not 
quantify the number of TH labeled cells to show how significant the difference was. 
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Since we were more interested to see whether GDNF could induce the local 
micro-environment to allow the production of newly generated neurons in the substantia 
nigra, we did not count the BrdU labeled cells in the dentate gyrus and the basal ganglia 
as we did in the previous studies. 
Although there was evidence of increased neurogenesis in response to several 
brain insults including seizure and ischemia (Magavi et al. 2000; Nakatomi et al. 2002), 
the 6-OHDA lesion did not induce the production of newly generated dopaminergic 
neurons in the substantia nigra as shown by our confocal study with BrdU and TH 
antibodies. 
Combined with the results of our earlier study with the 6-OHDA MFB lesion 
model, we believe that the absence of dopaminergic neurogenesis was neither due to the 
location and time frame of GDNF delivery, nor related to the extent of the lesion. Despite 
the existence of stem/progenitor cells locally, the substantia nigra may not offer a suitable 
environment for the production of new neurons. 
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Figure 5.1.A – HPLC results on dopamine tissue level in the striatum. 
The tissue level of dopamine in the caudate-putamen was compared 
between the GDNF treated group and the Citrate treated group. 
Although the GDNF recipients had higher DOPAMINE overflow in 
both sides of the striatum than the vehicle recipients, the difference was 
not significant. 
Right side: F=2.744, P=0.056; Left side: F=0.729, P=0.205.
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Figure 5.1.B – HPLC results on dopamine tissue level in the substantia 
nigra. The tissue level of dopamine was compared between the two 
treatment groups in the substantia nigra. The dopamine overflow in the 
right substantia nigra with GDNF recipients was significantly higher 
than that of the vehicle recipients. (*: P<0.05) 
Right side: F=3.662, P=0.039; Left side: F=0.181, P=0.339. 
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Figure 5.1.C – HPLC results on DOPAC tissue level in the striatum. 
The tissue level of DOPAC was compared between the two treatment 
groups in the substantia nigra. The DOPAC tissue level was 
significantly higher in the right striatum with GDNF recipients than 
that of the vehicle recipients. (*: P<0.05) 
Right side: F=4.457, P=0.028; Left side: F=0.044, P=0.419. 
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Figure 5.1.D. – HPLC results on DOPAC tissue level in the substantia 
nigra. The tissue level of DOPAC was compared between the GDNF 
treated group and the citrated treated group. The difference was not 
significant in either side of the substantia nigra. 
Right side: F=0.371, P=0.277; Left side: F=0.267, P=0.307. 
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Figure 5.1.E – HPLC results on HVA tissue level in the striatum. The 
tissue level of HVA was compared between the two treatment groups in 
the substantia nigra. The HVA tissue level was significantly higher in 
the right striatum with GDNF recipients than that of the vehicle 
recipients. (*: P<0.05) 
Right side: F=4.330, P=0.029; Left side: F=9.141, P=0.161. 
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Figure 5.1.F. – HPLC results on HVA tissue level in the substantia 
nigra. The tissue level of HVA was compared between the GDNF 
treated group and the citrated treated group. The difference was not 
significant in either side of the substantia nigra. 
Right side: F=1.310, P=0.137; Left side: F=0.162, P=0.347. 
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Chapter Six 
 
General Discussion and Conclusions 
 
In the past decade, GDNF has been identified as the most potent trophic factor for 
the dopaminergic neurons in the brain and the motoneurons in the spinal cord. 
Application of GDNF has increased dopaminergic cell number, cell size, axonal 
sprouting, and dopamine uptake in the brain of normal, aged and Parkinsonian animals. 
Besides, it may also exert function in the SVZ and hippocampus, where adult 
stem/progenitor cells exist and proliferate constitutively. 
The primary purpose of this study was to evaluate the general hypothesis that 
GDNF induces stem/progenitor cells to proliferate and differentiate into neurons in the 
basal ganglia and the dentate gyrus of the hippocampus. Four specific aims were derived 
from this overall hypothesis: first, we found that GDNF enhanced stem/progenitor cell 
proliferation in normal rat brain, but did not produce new dopaminergic neurons. Second, 
we examined the ultrastructure of the BrdU labeled cells in the striatum, hippocampus 
and substantia nigra with continuous infusion of BrdU. What we found is that the results 
of the first study were not due to limitations in the delivery of BrdU. In addition, any 
BrdU labeled cells that possessed features of differentiated cells showed characteristics of 
astrocytes. Then, we investigated the effect of continuous GDNF infusion on the 6-
OHDA MFB lesioned brain, and found increased BrdU proliferation in the hippocampus 
and the ipsilateral substantia nigra. There were no newly generated dopaminergic neurons 
observed under GDNF treatment even in response to the severe injury. Last, we explored 
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the involvement of neurogenesis in the protective effect of GDNF on the basal ganglia 
following a well established study. Although dopamine and DOPAC levels were 
increased with GDNF treatment, still no evidence of neurogenesis was detected in the 
substantia nigra. 
To simplify our experimental design, we used male Sprague-Dawley rats 
exclusively. Since ovarian hormones such as estrogen have been shown to increase cell 
genesis in the dentate gyrus (Tanapat et al. 1999; Ormerod and Galea, 2001; Daszuta et 
al. 2001), it would be interesting to investigate the effect of sex difference on 
neurogenesis in the future. 
The most exciting finding in this project was the potent bilateral effects of GDNF 
in stem/progenitor cell proliferation in the dentate gyrus of both normal and lesioned 
animals. This is the first time that GDNF has been linked to increased neurogenesis in the 
hippocampus. Neurogenesis has been found to correlate very well with the improvement 
of learning and memory in normal, aged and lesioned animals (Shors et al. 2001; 
Kemperman et al. 1997, 1998). In our experiments, GDNF administered intrastriatally 
through continuous infusion diffused through the entire ipsilateral hemisphere including 
the striatum, corpus callosum, cortex and substantia nigra (Fig.2.3). Since i.c.v. 
administration of GDNF improved spatial learning in aged rats as reported by 
Pelleymounter et al (1999), we would be very interested to test whether GDNF treatment 
in normal and lesioned rats could enhance learning and memory and to further evaluate 
the involvement of neurogenesis in this mechanism.  
While double-labeled BrdU+/NeuN+ cells in the dentate gyrus were observed 
with confocal microscopy procedures (Fig.2.10.) in normal and lesioned rats, we did not 
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detect any BrdU labeled cells in the hippocampus that have the characteristics of a mature 
neuron. Besides, about one fourth of the BrdU labeled cells detected in both the 
hippocampus and substantia nigra were located very close to a neuron. These cells may 
contribute to some of the “false positive” double labeling of BrdU and neuronal markers 
under traditional and confocal microscope. This indicates that confocal microscopy, 
though a successful technique in detecting colocalization of different cell markers, may 
be misleading unless all of the three different planes (x, y and z) were scanned on each 
section and some other techniques including electron microscopy were used as a 
supplementary. 
The nestin-immunoreactivity was more extensive in the SVZ and hippocampus of 
the GDNF-treated group than in the vehicle recipients, as depicted in Fig.2.7 and Fig. 2.8. 
These results further confirmed the increase stem/progenitor cell proliferation with 
GDNF infusion.  
In our electron microscopy study, BrdU labeled cells were either undifferentiated 
or showed characteristics of astrocytes. It has been reported (Doetsch et al. 1999 a, b; 
Filippov et al. 2003; Laywell et al. 2000; Seri et al. 2001) that astrocytes might serve as 
stem/progenitor cells that could give rise to mature neurons (Garcia et al. 2004). Our 
results were consistent with these observations and offered direct evidence that 
stem/progenitor cells might have ultrastructural characteristics of mature astrocytes. 
GDNF showed potent effects on stem/progenitor cell proliferation in the basal 
ganglia. It was difficult to compare the number of BrdU labeled cells in the caudate-
putamen between the two treatment groups without the interference of the local immune 
response toward catheter implantation; however, there was a significantly higher number 
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of BrdU positive cells in the contralateral striatum of normal animals with the GDNF 
treatment. The BrdU immunoreactivity was significantly higher in the substantia nigra of 
GDNF recipients under normal conditions or after severe 6-OHDA MFB lesions. Based 
on our electron microscopy study on normal animals, BrdU labeled cells were not 
undergoing apoptosis. Here we reported, for the first time, that GDNF promotes 
stem/progenitor cell proliferation in the basal ganglia. Since GDNF is a potent trophic 
factor on dopaminergic neurons, stem cell biology might be involved in the mechanisms 
by which GDNF exerts its functions. 
Normal animals, upon receiving GDNF, have a significantly higher number of 
dopaminergic neurons labeled with TH in the ipsilateral substantia nigra. Since we did 
not detect any newly generated neurons in the substantia nigra under GDNF/vehicle 
treatment, GDNF might simply increase the TH immunoreactivity instead of 
neurogenesis. Another explanation was that GDNF helped to promote locally presented 
dopaminergic precursors to differentiate through enhanced gliogenesis. 
Based on previous studies (Rakic, 2002; Lie et al. 2002), the local micro-
environment of stem/progenitor cells were critical for their differentiation. As described 
by Lie et al (2002), endogenous stem/progenitor cells exist in the substantia nigra and 
have the ability to proliferate into all cell lineages including neurons when isolated and 
cultured in vitro. They had the ability to differentiate into glial cells in vivo. Furthermore, 
these stem/progenitor cells could survive and differentiate into neurons when transplanted 
back into the hippocampus, where neurogenesis presents constitutively. No neurogenesis 
was found in the basal ganglia with GDNF treatment under normal conditions or with 
injury in our studies, suggesting that GDNF by itself may not be able to alter the 
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microenvironment in the substantia nigra and allow the differentiation of endogenous 
stem/progenitor cells locally present. 
With GDNF intrastriatal treatment one month after 6-OHDA MFB lesions, motor 
functions were not improved as measured by apomorphine-induced rotation tests. This 
suggests that the location and time point of drug delivery, as well as the severeness of the 
lesions, may be critical for GDNF to exert its function. The following study, with GDNF 
intranigral administration six hours before a partial 6-OHDA lesion, showed 
neurochemical improvements under GDNF treatment without neurogenesis. This further 
confirmed that GDNF alone might not be sufficient to induce neurogenesis despite its 
potent neuroprotective and neurorestorative effects on dopaminergic neurons. 
Up until now, there have been two reports on the observation of newly generated 
dopaminergic neurons either in the striatum of animals with intrastriatal TGFα treatment 
(Fallon et al. 2002), or in the substantia nigra of normal and MPTP lesioned animals 
(Zhao et al. 2003). As reported in the second paper, the rate of neurogenesis even doubled 
after MPTP lesions. Both papers were repeated carefully and independently with minor 
modifications by us and other groups (Cooper & Isacson, 2004; Frielingsdorf et al. 2004; 
reviewed by Lindvall et al. 2004). In all cases, the existence of neurogenesis could not be 
proved. Other groups also could not detect the presence of neurogenesis in the substantia 
nigra (Lie et al. 2002; Mao et al. 2001) using various experimental design. We suspect 
that the observation of neurogenesis in the basal ganglia may be “false positive” signals 
due to the limitation of cell markers (Nowakowski & Hayes, 2000; 2002) or the confocal 
microscopy as described above. 
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In each of our experiments, we observed the effect of GDNF only 28 days after 
the start of its delivery. This time point was chosen because significant structural and 
functional recovery of the nigrostriatal system has been reported in the lesion models 
being used by four weeks after GDNF treatment (Bowenkamp et al., 1995; Kearns et al., 
1997; Fox et al., 2001). As observed in our second study with BrdU infusion, many of the 
marker labeled cells seem to be uncommitted progenitors under the electron microscopy. 
Thus, further experiments are needed to extend the time point and investigate the long 
term effects of GDNF on neurogenesis. 
In conclusion, we are still many steps away from inducing endogenous 
neurogenesis in the substantia nigra, but the discovery that GDNF treatment induced 
prominent stem/progenitor cell proliferation gave us a new insight in understanding the 
mechanism of its function. In addition, the effects of GDNF on neurogenesis in the 
dentate gyrus and the hippocampus-associated learning and memory need to be further 
investigated with great promise. 
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